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ABSTRACT
EXPRESSION OF CBMP4 PROTEIN
AND ANTI-CBMP4 MONOCLONAL ANTIBODY PRODUCTION
by Xuezhi Li
Malformations during cardiac valve development are some of the most common
congenital heart defects. Recent studies on BMP4 in heart development reveal that this
secreted protein plays key roles in cardiac cushion formation, differentiation and cushion
cells apoptosis. While a few papers have investigated BMP4 transcription patterns at
various times during heart development, a clear mapping of cardiac BMP4 expression
domains has yet to be accomplished. Studies at the protein levels are particularly
hampered in the chick by the lack of suitable specific anti-cBMP4 antibodies. To address
this need, chick recombinant BMP4 was cloned, expressed and purified in both COS-7
cells and in E. coli for anti-cBMP4 monoclonal antibody (mAb) production. In addition,
a BMP4 synthetic peptide was used to produce anti-cBMP4 mAb that could be used for
future immunohistochemistry studies to map the spatio-temporal pattern of BMP4 protein
expression during heart development.
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Introduction
Congenital Heart Disease
Congenital heart malformation is the most common human birth defect and the
leading cause of death in the first year of life (Hoffman, 1995). It is estimated that the
US population of adults with congenital heart disease was about 8,000,000 in 2000
(Warnes, Liberthson, & Danielson, 2001). Most congenital heart malformation is due to
the defects of septation or valvegenesis events during embryonic heart development. For
example, one of the most frequently diagnosed disorders is atrioventricular canal defect
(AVCD), which accounts for 7.3% of all congenital heart abnormalities (Pierpont,
Markwald, & Lin, 2000). AVCD covers a spectrum of abnormalities. The partial form
of AVCD is caused by a deficiency in atrial septum primum (ASP) formation, whereas
the complete form is due to the absence of AV septum, resulting in the formation of a
single common atrioventricular canal (Digilio, Marino, Giannotti, Di Donato, &
Dallapiccola, 2000). The process of embryonic cardiogenesis has been extensively
studied at both the anatomical and molecular levels using animal models, enhancing our
understanding of the mechanisms underlying cardiac morphogenesis and the
pathogenesis of congenital heart defects.
Embryonic Heart Development
The heart is the first organ to form and function during vertebrate embryogenesis.
Heart development is a complex process that involves a series of cellular migrations,
fusions, and specific differentiations. Due to the evolutionary conservation of many of
these processes, major insights of embryonic cardiogenesis have been gained from the
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studies of chick embryos. In the pregastrula chick embryo, cells that contribute to the
heart are found within the posterior half of the epiblast (Hatada & Stern, 1994; Rawles,
1943). During early gastrulation stage, cardiac precursor cells migrate to a region of the
primitive streak caudal to Hensen's node. Thereafter, they migrate into the mesoderm
and spread anterolaterally, resulting in the formation of right and left precardiac
mesoderms (Garcia-Martinez & Schoenwolf, 1993; Rosenquist & DeHaan, 1966). At
Hamburger and Hamilton (HH) 6, the bilateral regions then condense, which later forms
a cardiac crescent that subsequently coalesces at the ventral midline to form a linear heart
tube. The heart tube is composed of a thin outer myocardium and an inner endocardium.
The myocardium secretes a thick extracellular matrix called the cardiac jelly that
separates the myocardium and endocardium (Kirby, 2002). The heart tube expands and
bends to the right side of the embryo and later the heart tube twists dramatically and
forms a d-loop. As the development proceeds, the heart tube dilates, elongates and twists
in a right-handed manner, realigning the prospective chambers so that the forming atrium
is to the left and cephalic to the ventricle. At the same time, presumptive cardiac
segments begin to appear, which make up the conus cordis or outflow tract (OT),
primitive right and left ventricles, atrioventricular canal (AVC), atrium, and the sinus
venous. After the completion of the d-loop, some of the endocardial cells of the OT and
AV segments of the single heart tube change their phenotype to that of mesenchymal
cells. These then migrate into the adjacent cardiac jelly to form endocardial cushion

tissue, the primordial of the valves and cardiac septa of the adult heart. This embryonic
phenomenon involves what is called epithelial-mesenchymal transformation (EMT). At
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this time, ectomesenchyme originating from the cardiac neural crest migrates into the
cardiac OT via the arterial pole. Thereafter, the endothelially derived mesenchyme and
the neural crest-derived mesenchyme develop the outflow septum, semilunar valves and
the aorticopulmonary septum, respectively. The AV endocardial cushion tissue develops
to form the leaflets of the AV valves and the AV septum. As development proceeds, the
aorticopulmonary septum, outflow septum, interventricular septum (muscular ridge of the
interventricular foramen), AV septum, and primary atrial septum come into alignment
and fuse with each other, resulting in the completion of the four-chambered heart. At this
point the heart resembles its mature form (Larsen, 2001; Nakajima, Yamagishi, Hokari,
& Nakamura, 2000).
TGF-0 Superfamily and Bone Morphogenetic Proteins
The regulatory factors involved in the process of septation and valvegenesis are
heavily investigated, with numerous studies indicating that members of the transforming
growth factor- /3 (TGF-/3) of signaling molecules are involved. The TGF-/3 superfamily is
composed of over 30 structurally related members with diverse functions in development.
Based on sequence homology and signaling mechanisms, the TGF- /3 superfamily
includes i) the TGF- /5 family, ii) the activin family, iii) the bone morphogenetic proteins
(BMPs), iv) the Vgl family, and v) other proteins, including glial-derived neurotrophic
factor and Mtillerian inhibitory factor (Hogan, 1996; Gilbert, 2003). The protein encoded
by TGF- (3 superfamily gene is synthesized as a large pre-protein, consisting of a
hydrophobic signal peptide, an N- terminal pre-domain and a C-terminal biologically
active peptide (Herpin, Lelong, & Favrel, 2004). After protein processing, only the

3

carboxy-terminal region contains the active mature peptide with the TGF-/3 domain.
Then the mature peptides are dimerized into homodimers (with themselves) or
heterodimers (with other TGF- jS peptides) and are secreted from the cell for various
functions (Gilbert, 2003).
The BMPs constitute the largest family. They were originally identified from
bone matrix using an ectopic bone formation assay (Wozney, 1992). To date, around 20
BMP family members have been identified and characterized. Based on sequence
homology, there are six main groups: i) the Dpp subgroup, related to Drosophila
decapentaplegic (dpp), consists of BMP2 and BMP4; ii) the 60 A subgroup, related to
Drosophia 60 A protein, consists of BMP5, BMP6, BMP7, BMP8 (Zhao, 2003); iii)
BMP3A and BMP3B; iv) BMP9 and BMP10; v) BMP 12, BMP 13 and BMP 14, and vi)
BMP11 and growth/ differentiation factor 8 (Chen, 2004).
BMPs are 30-38 kD homodimers that are synthesized as prepeptides of
approximately 400-525 amino acids. The mature C terminal domain of BMPs usually
contains 100-140 amino acid residues after protein processing and dimerizes for
bioactivity. BMP proteins act through type I and type II receptors that are single-pass
transmembrane proteins with serine/threonine kinase domains on the cytosolic side of the
plasma membrane. Both type I and type II receptor are required for signaling. Three
types of type I receptors have been shown to bind BMP ligands, and they are type IA
receptor (BMPR1A or ALK3), IB receptor ( BMPR1B or ALK6) and type IA activin

receptor (ActRl A or ALK2)(Koening et al., 1994, Macias-Silva, Hoodless, Tang,
Buchwald, & Wrana, 1998; Ten Dijke et al, 1994). Three type II receptors for BMPs

4

have also been identified and they are type II receptor (BMPR II), type II and IIB activin
receptors (ActR II and Act R IIB). Whereas BMPR1 A, BMPR IB and BMPR II are
specific to BMPs, ActRl A, ActR II and ActR IIB are also signal receptors for activins
(Kawabata, Chytil, & Moses, 1995; Yamashita et al., 1995). Signal transduction through
serine/threonine kinase receptors has been best characterized in the TGF-/3 receptor
system. It is likely that BMP receptors transduce signals in a similar fashion. Typically,
the ligand first binds to and activates a type II receptor homodimer which recruits,
phosphorylates, and activates a type I receptor homodimer, forming an active tetrameric
receptor complex. The type I receptor directly binds and phosphorylates a group of
regulatory proteins belonging to Smad family. In mammals, eight members of the Smad
protein family have been identified, and these have been grouped into three different
classes based on structures and functions (Balemans & Van Hul, 2002). One class of
Smads consists of the receptor-regulated Smads (R-Smads) that act as latent transcription
factors. R-Smads transiently associate with the type I receptor and are phosphorylated on
their C-terminus by the type I receptor kinase domain. Phosphorylated R-Smads then
interact with the co-Smad, Smad4, resulting in translocation of the heteromeric complex
to the nucleus where it interacts with cell-specific transcription factors to induce target
gene expression (Piek, Moustakas, Kurisaki, Heldin, & Ten Dijke, 1999). Binding of
different TGF-/3 family members to their respective receptors results in the activation of
different R-Smads. Smads2 and 3 are specifically activated by activin/ TGF-/3 signaling,

whereas Smads 1, 5 and 8 are activated upon BMP stimulation. The last class of Smads
consists of the inhibitory Smads, Smads6 and Smads7, which function as negative

5

regulators of signaling. Smad6 primarily regulates BMP signaling by competing with
Smad4 for binding to activated Smadl, resulting in the formation of an inactive
Smad6/Smadl complex (Hata, Lagna, Massague, & Hemmati-Brivanlou, 1998). Smad7,
which lacks the conserved C-terminal phosphorylation site of R-Smads, is unable to
translocate to the nucleus and downregulates BMP, activin, and TGF-/3 signaling by
inhibiting the phosphorylation of R-Smads through competition with R-Smads for type I
receptor binding (Hayashi et al., 1997).
Bone Morphogenetic Protein 4 and Functions
One member of BMP family is bone morphogenetic protein 4 (BMP4). It is a 405
residue pre-protein in the chick. It contains a signal peptide region from residue 1 to 19,
a pre-peptide region from residue 20 to 291 and a mature chain (cleaved posttranslationally) from residue 292 to 405, comprising an active carboxyl- terminal peptide
of 114 residues. There are four N-linked glycosylation sites at residue 114, 208, 343 and
362 respectively. Each BMP4 monomer is held together by disulphide bridges between
three pairs of cysteines in a conformation called the cysteine knot. BMP4 is a secreted
protein and its structure is closely related to BMP2. Thus, BMP4 is also named BMP2B.
BMP4 plays an important role in embryogenesis. Early studies using Xenopus
embryos indicate that BMP4 is a powerful ventralizing molecule. If the mRNA for
BMP4 is injected into Xenopus eggs, all the mesoderm in the embryo becomes
ventrolateral mesoderm, and no involution occurs at the blastopore lip (Dale, Howes,
Price, & Smith, 1992; Jones, Lyons, Lapan, Wright, & Hogan, 1992). Conversely,
overexpression of a dominant negative BMP4 receptor results in the formation of two
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dorsal axes (Graff Thies, Song, Celeste, & Melton, 1994; Suzuki et al., 1994). When
BMP binds to ectodermal cells, it activates the expression of genes such as msxl, which
induce the expression of epidermal-specific genes, while inhibiting those genes that
would produce a neural phenotype (Suzuki, Ueno, & Hemmati-Brivanlou, 1997). The
mechanism of ventral ectoderm (epidermis) induction is depended on the formation of a
BMP4 gradient. The gradient of BMP4 activity, largely established by organizersecreted BMP4 antagonists such as chordin, noggin, and follistatin through binding and
thus inhibition of BMP4 activity (Dale & Wardle, 1999; Harland & Gerhart, 1997)
specifies the different mesodermal territories along the marginal zone of the Xenopus
gastrula. In particular, high levels of BMP4 activity specify ventral mesoderm fates such
as blood, intermediate BMP levels specify more lateral mesoderm derivatives such as
kidney, and low levels of BMP activity (in the region closest to the organizer) specify
dorsal fates such as muscle (Winnier, Blessing, Labosky, & Hogan, 1995).
A large number of studies in several different species have implicated a key role
of BMP4 hematopoietic commitment. Huber et al. (1998) has demonstrated that BMP4
together with either basic fibroblast growth factor or activin A can induce the formation
of red blood cells from non-mesodermal structures using Xenopus embryos and explant
assays. Furthermore, hematopoietic commitment induced by the GATA binding
transcription factors GATA1 and GATA2 requires intact BMP signaling (Huber, Zhou,
Mead, & Zon, 1998; Maeno et al., 1996). Mice lacking BMP4 died between embryonic
day 7.5 to 7.9 (E7.5 to E9.5) exhibiting severe defects in mesoderm formation and the
embryos that survive up to E9.5 show defective blood islands (Winnier et al., 1995). In
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addition, it is recently demonstrated that BMP4, in combination with cytokines, promotes
hematopoietic differentiation of human embryonic stem cells (Chadwick et al., 2003).
BMP4 may act as an important positive regulator of both proliferation and survival of
human stem cells (HSCs). Bhatia et al. (1999) found that low concentration of BMP4
promoted proliferation and differentiation of CD34+CD38"Lin" cells while high
concentration of BMP4 extended the duration of stem cell activity in Nonobese
Diabetic/Severe Combined Immunodeficiency (NOD/SCED) mice transplanted with
purified HSC (CD34+CD38"Lin") from human hematopoietic tissue following ex vivo
culture in serum free medium. Thus BMP4 is acting as a survival factor, preserving the
sternness of the hematopoietic cells.
BMP4 is also involved in organ development. The lung appears from the ventral
foregut as two primary buds, each consisting three layers: the inner epithelium (of
endodermal origin), the surrounding mesenchymal stroma, and a thin outer mesothelium.
Early in development, the epithelium undergoes a stereotypic pattern of branching
morphogenesis to form the conducting airways, a process regulated by epithelialmesenchymal interactions (Cardoso, 2001). In vitro studies indicate that exposure of
lung explants and their associated mesenchyme to BMP4 results in stimulation of
branching and epithelia cell proliferation (Bragg, Moses, & Serra, 2001). BMP4 is
expressed in lung mesenchyme with the highest expression adjacent to the proximal
epithelium, including expression in parabronchial smooth muscle (PBSM) cells (Weaver,
Batts, & Hogan, 2003). Possibly, the mechanism of BMP4 regulating lung branching is
through inducing PBSM precursor cells differentiation into PBSM cell lineage (Mailleux,
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Kelly, & Veltmaat, 2005). PBSM cells are found surrounding the proximal air ways
(Yamada, Suzuki, Gejyo, & Ushik., 2002), and may participate in embryonic lung growth
by a stretch-induced signaling mechanism (Sparrow & Lamb, 2003). Fetal PBSM is
spontaneously contractile throughout gestation, resulting in the stretching of the fetal
pulmonary epithelium and mesenchyme (Schittny, Miserocchi & Sparrow, 2000). It is
possible that the contractility of PBSM may result in the release of growth factors,
signaling molecules, or the regulation of gene expression with consequent effects on lung
cell growth and differentiation (Nakamura & McCray, 2000).
Bone Morphogenetic Protein 4 and Heart
Gene expression and in vitro explant assays suggests that BMP4 is a key
myocardial signal in initiating epithelial-mesenchymal transformation (EMT) and driving
the formation and/or differentiation of the cardiac cushions (the precursor to the heart
valves and immediately adjacent areas). Because of its spatio-temporal patterns of
expression, BMP4 is, in fact, thought to play a role in induction and maturation of the
cushions in both the OFT and the AVC. Time course study of BMP4 mRNA expression
domain within the mouse developing heart tube by in situ hybridization found its
expression is restricted to the myocardium in cushion-forming segments of the AVC at
E9.5. At E10.5, however, BMP4 expression switched to the myocardium of the OFT,
becoming absent from the AVC (Jones, Lyons & Hogan, 1991). More recently, the
expression domain of BMP4 mRNA has been further investigated and its role in cushion
formation confirmed by another study using chick embryos to map the expression pattern
of BMP isoforms using in situ hybridization (Somi, Buffing, Moorman, & Van Den Hoff,
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2004). Somi et al. (2004) found that BMP4 was expressed in the distal myocardial
border of the OFT during recruitment of mesodermal cells to the OFT myocardium at
HH10-11. As heart development proceeded, BMP4 was expressed in the cardiomyocytes
that protruded into the mesenchyme during muscularization of the atrioventricular
cushions and the tricuspid valve at HH 33. In addition to studies focused on BMP4
transcripts expression patterns using in situ hybridization, the immunolocalization of
BMP4 protein expression was also investigated recently. Using polyclonal antibody to
immunolocalize the expression domain of BMP4, Keyes et al. (2003) demonstrated that
BMP4 was only expressed in myocardia, not in the cushions in both chick and mouse. At
chick E5 to E6, for example, BMP4 was expressed restrictly to the myocardium of the
OFT. BMP4, however, may not be acting alone. In vitro explant assay involving the
explanation of heart tube in three dimensional collagen gels indicates that BMP4 by
itself is unable to induce cushion formation, suggesting the involvement of additional
factors (Mjaatvedt, Lepera, & Markwald, 1987).
Investigation of BMP4 function in cardiac development has been hampered by the
early embryonic lethality of BMP4 null mutant embryos (Lawson et al., 1999). Jiao et al.
(2003) overcame this difficulty by combining use of a hypomorphic BMP4 allele with a
Cre/Loxp approach to manipulate levels of BMP4 expression specifically in
cardiomyocytes. Their findings, however, were contrary to previous hypotheses. They
showed that BMP4 was dispensable for the initiation of cushion formation but was
uniquely required for proper AV septation after cushions have formed. In the developing
mouse hearts, even BMP4 was completely deleted, the EMT was normally initiated. In
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contrast, after cushions have formed, a modest reduction and a more severe reduction in
BMP4 gene expression in mutant mice caused the partial and complete form of AVCD.
Nevertheless, the idea that many other BMPs (BMP2, BMP5, BMP6, BMP7, BMP10)
are coexpressed in the embryonic heart and may compensate for the loss of BMP4
(Dudley & Robertson, 1997; Lyons, Pelton, & Hogan, 1990; Lyons, Hogan, & Robertson,
1995; Neuhaus, Rosen, & Thies 1999; Somi et al., 2004) compromises their conclusion
that BMP4 was dispensable for initiation of cushion formation. Thus gene targeting
approaches require double or even triple knockouts to uncover the role of BMP4 during
heart development due to the overlapping expression pattern of BMP family.
Another theory as to the possible functions of the BMP4 in the early stage of heart
development is that BMP4 is involved in the initiation of an apoptotic molecular cascade
in a sub-population of cushion cells (Zhao & Rivkees, 2000; Abdelwahid, Rice,
Pelliniemi, & Jokinen, 2001). Existing evidence for an in vivo role for BMPs in the
induction of apoptosis is inconsistent. BMP4 has previously been shown to induce cell
death in tissue culture explants of the endocardial cushions of the OT and AV regions
(Zhao et al., 2000). Somi et al. (2004) made this theory more attractive. They found that
at the site of delamination, BMP4 mRNA was expressed at interface of myocardium and
cushion tissue. During digit formation, BMP4 was found to be essential in the regulation
of interdigital cell death (Merino, Ganan, Macias, Rodriguez-Leon, & Hurle 1999; Tang
et al., 2000). These observations suggested a role for BMP4 in mediating cell death in
delamination of the valve in order to make the valve move freely. However, Allen et al.
(2001) failed to find an increase in the levels of apoptosis in the cushions by
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overexpressing retroviral noggin (antagonist of BMP4) to inhibit BMP4 signaling.
Interestingly, mice deficient for intracellular BMP-signaling molecule, Smad 6
(inhibiting BMP4 signal transduction pathway), developed severe cardiac defects, with
hyperplasia of the cardiac valves and defects of septation in the OT (Galvin et al., 2000).
Taken together, no unequivocal evidence supports a role for BMP4 in the induction of
apoptosis in the developing heart.
Specific Aim
The objective of this research project was to produce anti-chick BMP4
monoclonal antibodies (mAbs) for use in a time-course study of BMP4 expression
domains during chick cardiogenesis.
Experimental Design
In order to produce anti-chick BMP4 monoclonal antibodies, two approaches
were carried on in parallel: i) Express recombinant chick BMP4 protein (cBMP4) in both
prokaryotes and eukaryotes and ii) direct produce monoclonal antibodies using cBMP4
peptides. Primer sets were first designed and tested to allow capture of i) the entire open
reading frame of cBMP4 and ii) that portion of the cBMP4 coding region giving rise to
the mature (normally proteolytically derived) fragment of cBMP4 (mcBMP4). Second,
the successfully amplified PCR products encoding the mature region were purified,
linearized and cloned into pcDNA4/HisMax, a mammalian cell expression vector
allowing the production of a His tagged BMP4 fusion protein. COS- 7 cells were then

transfected with this expression vector under optimized conditions to produce fusion HismcBMP4 protein. Finally, the His- tagged fusion protein was purified from crude cell
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lysate using a nickel-chelating affinity column. Although fusion protein expression was
verified by Western Blot in the crude cell lysate, initially weak expression levels coupled
with loss suffered during subsequent purification steps resulted in no detectable protein at
the final stage of purification. In an alternative approach, an E.coli expression system
was selected for protein expression and purification. A pGEX-KG vector carrying
mcBMP4 insert with the correct reading frame was constructed. E.coli BL-21 cells were
then transformed with this expression vector under optimized conditions to produce GST
fusion protein, GST-mcBMP4. Subsequently, this fusion protein was purified using a
GST affinity column and the expression of the fusion protein was verified by western blot.
In the second direct production approach, cBMP4 peptide was first designed
using bioinformatics' tools and synthesized by a commercial company. Mice were next
immunized following a standard protocol and immunization schedule. Once a specific
immune response in immunized mice had been verified, speenocytes were then harvested
and fused with sp2/0 cells for monoclonal antibody production. Clones were
subsequently screened for anti-cBMP4 specific monoclonal antibody production.
Materials and Methods
Mature Bone Morphogenetic Protein 4 Expression in Mammalian Cells
Total chick RNA isolation. Two dozen fertilized eggs were bought from Olivera
egg ranch (San Jose, CA), incubated for four days at 99±1°F with 100% humidity, and
rotated automatically during the incubation in the egg chamber. Incubation times were
extended to 4 days to correct for the temporary cessation of development that was found
to occur as a result of temperature drop during commercial storage and transportation of
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the eggs to the lab. At the end of incubation, chick embryos were harvested surgically,
and immediately put into RNAlater solution (Ambion) to inactivate the Rnase activity as
rapidly as possible. Net weights of the chicken embryos were obtained in these initial
process steps.
Chick total RNA was isolated using reagents supplied in Ambion's ToTALLY
RNA™ Total RNA Isolation Kit (Cat#AM1910) and following the manufactures
recommended protocol. Chicken embryos were transfered to a 50 ml conical tube
containing lOx volume of Denaturing reagent (each mg of tissue represents about 1 ul of
volume). Tubes were kept on ice and the tissue homogenized using a mechanical
homogenizer and stainless steel rotor. The tissue lysate was collected, poured into screwcapped polypropylene Sorval tubes and centrifuged at 12,000xg for 3-5 min at 4°C to
pellet debris. Harvested supernatants were transferred into a 50 ml conical tube. The
volume measured was defined as the starting volume. One starting volume of phenol:
chloroform: isoamyl alcohol (25:24:1, PH 7.5) was then added to the lysate, the mixture
vigorously vortexed for 1 min, incubated on ice for 15 min, and then centrifuged again at
12,000xg for 15 min at 4°C. Following this centrifugation, the upper aqueous phase was
harvested, its volume measured, and the solution transferred to a new 50 ml conical tube.
An amount of Rnase free sodium acetate (3M, PH 4.5) equal to 1/9 th the volume of the
transferred aqueous phase was added. The mixture was agitated for 10 seconds to create
a homogeneous solution. Next, one starting volume of acid-phenol: chloroform (AP: C)
was added to the adjusted aqueous phase. The solution was vortexed for 1 min, stored on
ice for 15 min and then centrifuged at 12,000xg for 15 min at 4°C. The aqueous phase
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was transferred to a new RNase-free polypropylene tube (with capacity at least twice the
volume of this harvested aqueous phase) and the total RNA then precipitated by adding
an equal volume of isopropanol with subsequent mixing. The RNA was allowed to
precipitate overnight -20°C. After the incubation was complete, the preparation was
centrifuged at 12,000xg for 15 min at room temperature. The supernatant was decanted
off and the residual salts was removed by gently vortexing (washing) the pellet using
freshly made 70% ethanol. RNA was recovered by centrifugation for 5-10 min at 3000xg
at room temperature. The final RNA pellets were then resuspended in the desired volume
of DEPC water containing 0.1 mM EDTA (100 (xl per 100 mg of starting material) and
the material stored at -80°C until needed (White, 2004).
PCR amplification of chick mature cBMP4. The entire coding region of cBMP4
was amplified using gene specific primers according to the published cBMP4 sequence
from GenBank (Accession number: X75915). Complete complementary primers were
designed for blunt end ligation using Vector NTI (Invitrogen). Sense primer was 5'
ATGATTCCTGGTAACCGAATGC3'; Antisense primer was
5'AGGGAAGGGGTCAGCG 3'. The sense primer started at nucleotide #1 while the
antisense primer started at nucleotide #1228. The total number of nucleotides amplified
was 1228 bp. RT-PCR was employed using an OneStep RT-PCR kit from Qiagen (Cat#
210210) to generate ds cDNA from chick total RNA under the standard conditions.
RT-PCR reaction conditions were as follows: lx RT-PCR reaction buffer

(containing 15mM MgCb), dNTP mix 0.2 mM each, primer 0.6 uM each, 1.3 ug chick
total RNA and 1 unit of enzyme mix in a 50 ul reaction volume. RT-PCR amplification
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was carried out at 50°C for 30 min, 95°C for 15 min followed by 40 cycles of 94°C for 30
Sec, 65.9°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min.
The mature region of cBMP4 was amplified using gene specific primers
(complete complementary) designed for blunt end ligation using Vector NTI (Invitrogen).
Sense primer was 5'AGCCCCAAGCACCACGGTTC3'; Antisense primer was 5'
GGGAAGGGGTCAGCGGCAC3'. The sense primer started at nucleotide #874, while
the antisense primer started at nucleotide #1219. The total number of nucleotides
amplified was 354 bp. Standard PCR was employed to amplify the mcBMP4 using the
full length cBMP4 PCR product as template. Taq PCR Core Kit from Qiagen (Cat#
201223) was used to set up PCR reaction following manufactures instructions.
PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15
mM MgCl2), dNTP mix 0.2 mM each, primer 0.5 uM each, 100 ng cBMP4 PCR product
and 1 unit of Taq polymerase in a 50 ul reaction volume. PCR amplification was carried
out at 94°C for 3 min, followed by 30 cycles of 94°C for 30 sec, 62°C for 1 min, 72°C for
1 min, and a final extension at 72°C for 10 min.
Subcloning of mature cBMP4 gene into a mammalian cell expression vector. The
pcDNA4/HisMax mammalian cell expression vector from Invitrogen (Cat # V864-20)
was selected to produce recombinant mcBMP4. Major features of this vector includes a
CMV promoter for high level expression in a wide range of mammalian cells, a QBI
SP163 translational enhancer for increased levels of recombinant protein expression, an
N-terminal peptide encoding the Xpress™ epitope, a polyhisidine metal-binding tag, and
an enterokinase recognition site for tag removal.
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The expression vector was first linearized using Kpnl restriction enzyme and
repurified. The linearized vector was next given blunt ends by treatment with T4 DNA
polymerase (New England Biolab, cat# M203S) and reaction buffer at 12°C for 20
minutes. The blunt end reaction contained lx T4 DNA polymerase buffer, 100 ug/ml
BSA, 0.1 mM each dNTP mix, 0.3 unit of T4 DNA polymerase and 1 pmole of Kpnl
digested vector in a 50 ul reaction. The digested vector was then treated with Aquatic
Phosphotase (New England Biolab) for 15 minutes at 37°C to generate dephosphorylated
ends. The dephosphorylation reaction contained lx aquatic buffer, 1 unit of Aquatic
Phosphotase and the previously end-converted vector in a 50ul reaction.
The amplified mature cBMP4 PCR product was ligated into the linearized and
dephosphorylated blunt ended expression vector. The ligation reactions were performed
according to Novagen's protocol described in pST Blue Perfectly Blunt Cloning kit (Cat#
70191). The plasmid constructs were transformed into NovaBlue Singles competent cells
(part of Perfectly Blunt Cloning kit) according to the manufacturer's protocol. Cells were
plated into IPTG (0.5mM)/Xgal (80 ug/ml)/Amp (100 ug/ml)/LA plates, grown
overnight at 37°C, and white colonies were picked and subcultured into a gridded LA
plate and incubated overnight. Next day, 10 colonies were picked to perform colony
PCR for the purpose of identifying the colonies carrying the desired cBMP4 insert.
Colony PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15
mM MgCb), dNTP mix 0.3 mM each, primer 1.5 uM each, lOul cell lysate and 1 unit of
Taq polymerase in a 25 ul reaction volume. PCR amplification was carried out at 94°C
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for 3 min, followed by 30 cycles of 94°C for 30 sec, 62°C for 1 min, 72°C for 1 min, and
a final extension at 72°C for 10 min.
A colony carrying the mature cBMP4 insert was selected, cultured using LB broth
with 50 ug/ml Ampicillin, and grown with shaking at 225 rpm overnight at 37°C.
Plasmid DNA was isolated the following day according to Qiagen's minielute kit
protocol. Plasmid concentration was determined using Nanodrop and sent out to Gene
Gateway (Hayward, CA) for DNA sequencing using both T7 (flanking the insert
upstream) and BGH primers (flanking the insert downstream) to confirm both the
orientation and nature of the insert.
Culture ofCOS-7 cells for transfection. COS-7 cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA). The complete medium used
for culturing the cells was DMEM supplemented with L-gultamine, penicillinstreptomycin, and 10% heat-inactivated fetal calf serum (FCS). A total of 2X10 5 cells
were seeded in a Falcon 25 cm2 tissue culture flask with 12 ml culture medium, and the
cells were incubated in a 37 °C incubator with 5% CO2 and 99% humidity. The cells
were examined daily using inverted microscope to ensure healthy growth and no
contamination. Every 2-3 days, cells were subcultured at the ratio of 1:4 by standard
trypsionization (White, 2004). The old medium was removed followed by rinsing the
cells with pre-warmed PBS. Then the adherent cells were detached from the bottom of
the flask by 2 ml 0.2% (W/V) trypsin-EDTA (1 mM) treatment about 5 min at 37°C.

After the cells were detached, 6 ml of complete medium were added to inactivate the
trypsin. Four new flasks containing 7 ml of the fresh medium were prepared. A 2 ml
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volume of cell suspension was transferred to each new flask, and incubated in the CO2
incubator.
COS-7 cells transfection condition optimization. In order to access the
transfection efficiency, pcDNA/HisMax/lacZ plasmid from Invitrogen (part of
pcDNA4/HisMax mammalian cell expression vector) was used as positive control to
optimize the transfection condition based on the /J-galactosidase expression. Mocktransfected cells in absence of any DNA were also used as negative control to provide
protein background.
COS-7 cells were transiently transfected using lipofectamine 2000 reagent
(Invitrogen) following the manufacture instructions. One day before transfection, cells
were passaged as described earlier and counted using Trypan Blue dye and a
hemocytometer. A total of 5x105 cells in 2 ml growth medium without antibiotics was
seeded on a cover slip (10cm2 surface area) placed in a 6- well plate so that cells would
be 90-95% confluent at the time of transfection. The medium used for transfection was
Opti-MEM I Reduced Serum Medium (Invitrogen), with L-glutamine added to OptiMEM I prior to use. Antibiotics and serum lower the transfection efficiency by either
disturbing the cells or interfering with the liposome mediated mechanism of DNA
transfer. Therefore, an hour before transfection, complete medium was removed, and the
cells rinsed with CMF-PBS to remove the trace of serum-containing medium. Finally, a
total of 2 ml Opti-MEM I was added to each well, and the incubation was continued.
For each transfection sample, the complex was prepared using a DNA mass to
Lipofectamine 2000 volume ratio of 1 (ug): 2.5(ul) or 1 (ug): 3 (ul) to optimize the
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transfection. For a DNA to Lipofectamine ratio of 1:2.5, DNA sample was prepared by
diluting 4 ug of pcDNA/HisMax/lacZ into 250 ul of Opti-MEM I medium. For a DNA
to Lipofectamine ratio of 1:3, DNA sample was prepared by diluting 3 ug of
pcDNA/HisMax into 250 ul of Opti-MEM I medium. In another tube, 10 ul
lipofectamine reagent were mixed with 240 ul of Opti-MEM I for 1:2.5 DNA to
lipofectamine ratio. Nine microliter of Lipofectamine reagent was mixed with 240 ul of
Opti-MEM I for 1:2.5 DNA to lipofectamine ratio. After 5 minutes incubation of
lipofectamine-Opti-MEM I reagent, the lipofectamine and DNA solution were combined,
mixed gently and incubated for 20 minutes at room temperature to allow for the
formation of liposome-DNA complexes. Finally, 500 ul Opti-MEM I was removed from
each well, and replaced by 500 ul of lipofectame-DNA complex solution. The plate was
returned to incubator to incubate for 4-6 hours. Following incubation, the medium was
removed totally and complete medium were added. Cells were incubated continuously
and observed for transient expression over 5 days. In addition to a positive control,
mock- transfected cells were also used as a negative control.
Staining cells for /3-galactosidase activity. At the end of incubation, cells were rinsed
twice with sterile CMF-PBS, then fixed by adding 2 ml glutaraldehyde solution (0.25%
v/v in CMF-PBS) and incubated at room temperature for 15 minutes. Cells were rinsed
again three times with 5 ml CMF-PBS to remove residual glutaraldehyde. Finally, 2 ml
X-Gal Working Solution (0.2% w/v X-Gal in CMF-PBS supplemented with 2 mM
MgCl2, 5 mM K4Fe (CN) 6 -3H 2 0 and 5 mM K3Fe (CN) 6 was added to each well and
incubated 20 minutes. At the end of the staining period, X-Gal solution was removed and
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CMF-PBS was added for better viewing of the stained cells. Stained cells were observed
under the inverted microscope and images recorded using a Nikon model digital camera.
Preparation of cell extracts. At 48 hour post transfection, cells were rinsed with
PBS and harvested in 1 ml PBS using a rubber cell scraper. The harvested cells were
transferred into a 15 ml conical tube and centrifuged at 1500xg for 5 minutes. The
supernatant was discarded, and the pellet was resuspended in 2 ml cell lysis buffer
containing 1% Nonidet P-40, 150 mM NaCl, and 50 mM Tris-HCl at PH 7.8. A
mammalian tissue protease inhibitor cocktail containing AEBSF, Aprotinin, Bestatin
hydrochloride, E-64, EDTA and Leupeptin hemisulfate salt (Sigma) was also added to
the cell suspension to prevent protein degradation by endogenous enzymes. The cell
suspension was incubated on ice for 15 min. Following the incubation, the cells were
further lysed by two freeze-thaw cycles using liquid nitrogen and 42°C water bath. Cells
were then sonicated using Sonifier Cell Disruptor model 350, set at 50% duty cycle and
power output setting of 5.5 for 5 cycles with 20 s burst and 40 s cooling period for each
cycle. After lysis, the cell lysate was centrifuged at 1500xg for 10 min. Then the
supernatant containing cell extract was collected and stored at -80°C.
Protein purification using Probond™ purification system. The fusion protein had
six tandem histidine residues on its N- terminus, and this polyhistidine tag has a high
affinity for a resin containing nickel ions. Therefore, when the tagged protein was
applied to a pre-filled ProBond™ column with ProBond™ nickel-chelating Resin

(Invitrogen, Cat# K850-01), it was captured by the column's nickel-chelating resin. The
fusion protein was later eluted with an imidazole gradient under native conditions.
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Imidazole has a similar structure to that of histidine and can thus desorb tagged protein
from the column by competitive substitution. All the buffers used in the system had a pH
of8.
The purification of the His-mcBMP4 fusion protein was performed according to
the manufacturer's protocol, hi brief, 2 ml of nickel-chelating resin was poured into a 10
ml purification column and allowed to settle completely by gravity. The supernatant was
gently removed by aspiration and the column pre-equilibrated by washing twice with 6
ml sterile distilled water and three times with 6 ml Native Binding Buffer (20 mM
sodium phosphate and 500 mM sodium chloride, pH 8). Prior to loading, 5ml of the
concentrated cell extract was raised to 8 ml by adding Native Binding Buffer. Following
this dilution step, the sample was applied to the column and mixed with the resin for 60
min at room temperature with gentle agitation to keep the resin suspended in the lysate
solution. After the 60 min incubation, the column was washed twice with 8 ml Native
Binding Buffer and three times with 8 ml Native Wash Buffer (20 mM imidazole, 20 mM
sodium phosphate and 500 mM sodium chloride, pH 6) to remove non-binding and/or
low affinity non-specifically bound protein. Following this washing step, the fusion
protein was eluted with 10 ml Native elution buffer with an imidazole gradient. The
gradient was generated by applying four elution buffers (pH6) in increasing imidazole
concentration (50 mM, 200 mM, 300 mM, and 500 mM) into the column. The eluented
fraction was collected from the column and each fraction was analyzed with SDS-PAGE.

Western blot analysis. A 4-12% Bis-Tris gradient NuPage minigel (Invitrogen)
was used to verify the efficiency of protein purification. A western blot was then used to
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verify the presence of recombinant His- mcBMP4 fusion protein. Each sample was
diluted using 4x sample buffer (Invitrogen) and heated at 70°C for 10 min. The samples
were cooled and quickly centrifuged to remove insoluble derbies and loaded into each
wells of the gel. MES-SDS buffer (50 mM MES, 50 mM Tris base, 0.1% SDS, 1 Mm
EDTA pH 7.3) was used as the running buffer. The gel was run at a constant 200 v for
35 min. Following electrophoresis, the proteins separated in the SDS-PAGE gel were
electrophorically transferred to a PVDF membrane (pre-wet in methanol). The XCell II
blot Module apparatus was assembled according to manufacturing protocol and the
transfer was conducted at a constant 30 V for 1.5 hour using NuPAGE transfer buffer (25
mM bicine, 25 mM bis-Tris, 1 mM EDTA PH 7.2). After the transfer, the gel was
exposed to Coomassie blue stain for overnight to evaluate the transfer efficiency. The
membrane was stained in Ponceau S solution containing 0.5% (w/v) Ponceau S and 1%
(v/v) glacial acid for 10 min, and then rinsed with DI water.
To develop the immunoblot, the PVDF membrane was placed in blocking buffer
(pH7.4) for 1 hour at room temperature. The blocking buffer was prepared by adding 2 g
of BSA to a liter of PBS containing 0.05% Tween 20. The membrane was then incubated
with primary antibody (anti-Xpress antibody, a mouse monoclonal IgG from Invitrogen)
diluted 1:5000 in blocking buffer at 37°C for 2 hours. The primary antibody directed
against the Xpress epitope was removed after one hour, and the blot washed with
blocking buffer 5 times over 30 min. After washing, the membrane was incubated with

the secondary antibody (rabbit anti-mouse IgG-AP conjugate, Sigma) diluted 1:5000 in
blocking buffer for 1 hour at room temperature. After incubation, the membrane was
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washed 3 times with blocking buffer and twice with PBS/Tween 20 over 30 min. Finally,
the membrane was rinsed with water and developed using the BCIP/NBT-substrate
(SIGMA FASTA BCIP/NBT Cat# B5655) for 5 min. After developing, the membrane
was washed in DI water and then air-dried.
Mature cBMP4 Protein Expression in E.coli
Subcloning mature cBMP4 into a bacterial expression vector. The mature region
of cBMP-4 was also amplified using gene specific primers designed by Vector NTI
software (Invitrogen). Sense primer was 5'
CGAAGGATCCAGCCCCAAGCACCACGGTTCCC 3'. Antisense primer was 5'
AACAAAGGATCCGTCAGCGGCACCCGCACCCCTC 3'. The sense primer started at
nucleotide #874, while the antisense primer started at nucleotide #1219. The total
number of nucleotides amplified was 370 bp. Standard PCR was employed to amplify
the mature cBMP4 using the full length cBMP4 PCR product by Qiagen's Taq core kit.
PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15 mM
MgCl2), dNTP mix 0.2 mM each, primer 0.5 uM each, 100 ng cBMP4 PCR product and
1 unit of enzyme mix in a 50 ul volume. RT-PCR amplification was carried out at 94°C
for 3 min, followed by 30 cycles of 94°C for 30 sec, 67.5°C for 1 min, 72°C for 1 min,
and a final extension at 72°C for 10 min.
The expression vector pGEX-KG was kindly provided by Dr. Soto. Major
features of this vector include a Glutathione S-transferase (GST) fusion tag and a

thrombin cleavage site. Since GST is highly soluble, recombinant protein fused with
GST tag could increase solubility. In addition, GST processes enzymatic activity. The
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level of fusion protein expression could be estimated by detecting GST activity.
Thrombin cleavage site is located right after GST for the convenience of tag removal.
The vector was digested using BamHI, then dephosphorylated using Aquatic
phosphatase to prevent vector religation. The mcBMP4 PCR product, also digested using
BamHI, was then ligated to the vector according to Novagen's protocol described in pST
Blue Perfectly Blunt Cloning kit, and transformed into E.coli (BL-21) competent cells
(Stratagene) according to manufacturer's protocol. Cells were plated into LA /Amp (100
)ig/ml) plates and grown overnight at 37 °C. The next day, 10 colonies were picked to
perform colony PCR for the purpose of identifying the colonies carrying the desired
cBMP4 insert. A colony carrying what appeared to be mcBMP4 insert was selected,
cultured using LB broth with 50 p.g/ml Ampicillin, and grown with shaking at 225 rpm
overnight at 37°C. Plasmid DNA was isolated the following day according to Qiagen's
minielute kit. Plasmid concentration was determined using Nanodrop and sent out to
Sequetech (Montain view, CA) for DNA sequencing using both pGEX3 and pGEX5
primers.
Screening PGEX recombinant for fusion protein expression. Several colonies of
E.coli transformed with the pGEX recombinants were picked for inoculation into separate
tubes containing 2 ml 2xYTA medium containing 16 g/L trytone, 10 g/L yeast, 5 g/L
Nacl and 100 ug/ml Ampicillin. The liquid culture was grown to an OD 6oo of 0.6-0.8
with vigorous agitation at 37°C. Cells were induced for two hours by adding 20 ul 100

mM isopropyl-(8-D-thiogalactoside (IPTG) (final concentration ImM), and the liquid cell
culture was then centrifuged at 500xg for 5 min. The cells were spun down and lysed
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using sonication in 10s burst with 20s rest. The crude cell lysate was centrifuged for 10
min at 7000xg again to remove insoluble material. The supernatant was harvested and
added into 50% slurry of Glutathione Sepharose 4B pre-equilibrated in ice cold PBS (pH
7.3). After 30 min incubation, sample was spun down again at 500xg for 5 min to
sediment Glutathione Sepharose 4B with recombinant protein attached. PBS (pH7.3) was
used to wash the sample three times. The fusion protein was eluted with elution buffer
(pH 8.0) containing 50 mM Tris-HCl, 10 raM reduced Glutathione. The eluted fraction
was analyzed by 4-12% pre-casted No vex NuPAGE gel (Invitrogen).
Fusion protein expression optimization. After the candidate expressing
recombinant protein was selected, important factors such as growth temperature and
induction conditions have been evaluated to achieve optimal protein expression.
A selected candidate colony was subcultured overnight at 37°C. Several colonies
were picked and transferred into separate tubes containing 40 ml 2xYTA medium. Cells
were cultured either at 30°C or 37°C until its OD 6oo reached about 0.6-0.8. Five different
IPTG concentrations (0.1 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1 mM) were added into
the liquid culture, and the cells were induced for different time period (2 hours, 4 hours, 6
hours, 8 hours and 10 hours). After induction, cells were lysed by sonication as
previously indicated. The supernatant was harvested and the relative level of GST fusion
protein expression was analyzed by GST activity using CDNB (l-chloro-2, 4dinitrobenzene) as the substrate. The CDNB solution contains 0.1 mM KH2PO4 (pH 6.5),
ImM CDNB and ImM reduced glutathione. Eight hundred microliter of CDNB was
transferred into one UV-transparent cuvettes containing 50 ul of the cell lysate
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supernatant and the absorbance was measured at 340 nm at 1 min invervals for 5 min.
A34o/min/ml was calculated as a value to indicate relative GST fusion protein content.
AA34o/min/ml= [A340 (t2)-(ti)]/ (t2-ti) (ml sample added), where A340 (t^) =absorbance at
340 nm at time t2 in min. (ti) =absorbance at 340 nm at time ti in min.
Mature cBMP4 protein expression and purification in E.coli. After the
expression condition was optimized, 100 ml of cells (2 liter cells for large scale) were
grown and induced at the optimized condition. Cell pellets were collected and sonicated
as previously described for small scale protein expression in 100 ml. Cells were lysed
using Bug Buster reagent (Novagen, Cat# 70584) supplemented with 0.1 raM PMSF
solution for large scale protein expression in 2 liter. A crude cell lysate was purified
using Glutathione Sepharose 4B beads as described above. Western Blot analysis was
employed to verify the expression of fusion protein. The detailed procedures were
described in previous section. The primary antibody was rabbit anti- GST polyclonal
antibody from GE health care at a 1:1000 dilution. The secondary antibody was goat
anti-rabbit IgG-HRP polyclonal antibody from Sigma at a 1:2000 dilution.
Monoclonal Antibody Production Using Synthetic Peptide
Selection of synthetic peptides. The complete sequence of chick BMP4 was
obtained from the protein sequence database of the National Center of Biotechnology
Information (http://www.ncbi.nlm.nih. gov/). The antigenic region of the mature cBMP4
protein was analyzed using the Protean function (protein structure analysis & prediction)

of the Lasergene software from DNASTAR to predict the peptide's secondary structure,
hydrophilicity, surface availability and antigenicity. In addition, the amino acid sequence
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of cBMP4 was also submitted to Alpha Diagnostic International (San Antonio, TX) for
an independent antigenicity analysis.
To ensure that the selected regions were unique to chick BMP4 rather than
common family member, the complete mcBMP4 amino acid sequence was compared to
the sequence of its closest family member (chick BMP2) and BMP4 sequences in two
other species (human and mouse). The amino acid sequences of mouse BMP4, human
BMP4, chick BMP4, mouse BMP2, Human BMP2 and chick BMP2 were imported into
Biology Workbench (http: //seqtool.sdsc.edu/CGI/BW/cgi) from the protein sequence
database. One peptide sequence SPKHHGSRKNKKNCRRH was selected for synthesis.
Manufacture of synthetic peptides. Chick BMP4 peptide was manufactured by
Alpha Diagnostic International (San Antonio, TX). Ten milligram of cBMP4 peptide
(average mass: 2071.0 g/mole) was synthesized at 100% purity. Six milligram of cBMP4
peptide was coupled to 3 mg of keyhole limpet hemocyanin (KLH) using glutaraldehyde
(GLUT) coupling method. A cBMP4 -KLH conjugate was supplied as 2 mg/ ml solution
in PBS and stored in 0.3 ml aliquots at -70 °C. The remaining 4 mg of unconjugated
cBMP4 peptide was supplied in a powder form and stored at -70 °C.
Animals. Female BALB/C mice were purchased and taken cared by University
Animal Care (UAC) Personnel according to approved guidelines in IACUC (Institutional
Animal Care and Use Committee) protocol No.867 (Appendix 1).
Mice immunization for screening assay. Three mice were immunized with
cBMP4-KLH conjugated peptides following the immunization schedule (Table 1). In
brief, one hundred microgram conjugated peptides in complete Freund's adjuvant (CFA)
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(0.3 ml) from Sigma were injected into each mouse via Intraperitoneal (IP) routes for the
first immunization. One hundred microgram conjugated peptides in incomplete Freund's
adjuvant (IFA) (0.2 ml) from Sigma were injected into each mouse subcutaneously (SC)
for the second immunization. One hundred microgram conjugated peptides only (0.2 ml)
were injected into each mouse subcutaneously for the third and fourth immunization.
Blood samples were collected as indicated by UAC personnel. Blood samples were
combined and allowed to stand at room temperature for 20 min to allow the clot to form,
and then samples were centrifuged for 10 min at 12,000rpm to prepare serum. After the
immune response has been verified by ELIS A, mice were primed with 0.1 ml pristine 3
days before injection of SP2/0 mouse myeloma cells. Then 1X106 SP2/0 cells (in 0.2 ml
PBS) were injected into mouse abdomen via IP route. A week later, mice ascites were
harvested. Mice which exhibited moderate abdominal distention, lack of appetite, pale
skin and an increase of respiratory effort were induced to narcosis using carbon dioxide
and cervically dislocated under supervision of ACF staff. Ascites was withdrawn using
an 18 gauge needle post -mortem by peritoneal cavity tapping. Ascites samples from
three mice were pooled together for optimizing the screening assay.
Screening assay optimization and antibody specificity analysis by ELISA.
Screening of specific antibody producing hybridomas is a very critical step since the
success of this project is largely dependent on a reliable screening assay for estimating
the immune response of the mice and selecting antibody producing hybridoma cells. The
amount of antigen required to coat each plate and the dilution of primary immune serum
and secondary antibody thus needed to be optimized.
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The specificity of the antiserum was analyzed by ELISA using the following
protocol. Polystyrene 96-well plates (Nalgene Nunc International, Rochester) were
coated with cBMP4 peptides in PBS solution (lOug/ml) overnight at room temperature.
The next day, the peptide solution was discarded and the blocking buffer containing 10%
skim milk in water was added into each well. The plate was blocked at room temperature
for one hour. After 1 hour blocking reaction, the plate was washed three times using PBS
with 0.05% Tween. Half of the plate was then incubated with 100 ul of different
dilutions of immune or pre-immune sera for one hour at room temperature, while the
other half of the plate was incubated with 100 ul of different dilutions of immune sera
pre-absorbed with 500 ng antigenic cBMP4 peptide. After incubation, wells were
washed again three times and treated with 100 ul horse radish peroxidase (HRP)
conjugated rabbit anti-mouse IgG (Sigma) at 1:500 dilution for one hour at room
temperature. Next, the wells were washed five times and incubated with 0.1 M 3, 3', 5,
5'-Tetramethylbenzidine (TMB) (Sigma). The absorbance value at 405 nm was then
measured using an automatic ELISA plate reader.
Table 1. Mice immunization schedule for screening assay
Week
1

Procedure
Preimmune blood sample
o

1 antigen/ adjuvant injection (1:1 antigen in CFA, 0.3 ml IP)
3

2° antigen/ adjuvant injection (1:1 antigen in IFA, 0.2 ml SC)

5

3 antigen/ adjuvant injection (antigen in saline, 0.2 ml SC)

7

4 antigen/ adjuvant injection (antigen in saline, 0.2 ml SC)
Immune blood sample collection
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Cell fusion for monoclonal antibody production. After the specificity of the mice
immune response to cBMP4 peptides were verified by ELISA, three mice were
immunized again following the protocol indicated above. After the immune response has
been verified by ELISA, two mice showing the strongest immune response were
sacrificed by cervical dislocation, and their spleens were harvested in a sterile manner.
The spleen was gently dissociated mechanically by pressing the tissue against a sterile
nylon screen and the spleenocytes were isolated by layering the cell suspension onto 10
ml Ficoll density medium. Cells were then centrifuged cells at 600xg for 20 min in Ficoll
density medium. Approximately 1x10 of the isolated spleenocytes were fused with
lxlO 7 SP2/0 cells in 50% polyethylene glycol (PEG) fusion medium slowly. The fused
cells were then transferred into hypoxanthine aminopterin thymidine (HAT) medium and
aliquoted into several 96-well tissue culture plates and incubated at 37° C. Hybridomas
were screened one week after cell fusion by ELISA.
Results
Bone Morphogenetic Protein 4 Expression in Mammalian Cells
Total chick RNA isolation. Total RNA was isolated from chick embryos using
Ambion's Total RNA system. The concentration of total RNA was determined by
measuring RNA's absorbance at 260 nm (OD260 nm). The purity of total RNA was also
estimated by measuring the ratio of UV absorbance at 260& 280 nm. Finally, the
integrity of total RNA sample was evaluated by 2% agarose gel electrophoresis. From 12
chick embryos (about 1.5 g), 9.2 mg total RNA (680 |il) was isolated with a
concentration of 13.67 ug/ul From gel analysis (Figure 1), the total chick RNA was
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28S
18S

5S
Figure 1. Analysis of different amounts of total RNA isolated from day 4 chick
embryos using 2% agarose gel electrophoresis. Samples were run in TAE buffer at
100V for 60 min using 2% of E- gel. Lane 1= 3 ug total RNA; Lane 2= 2 ug total
RNA; Lane 3= 1 ug total RNA. Lane 4= lkb MW ladder.

1228bp

354bp

Figure 2. Gel Analysis of cBMP4 inserts amplified from chick total RNA using PCR.
Samples were run in TAE buffer at 100V for 60 min using a 1% agarose gel. Panel A
shows the amplified cBMP4 insert containing the entire open reading frame. Lane 1=
1228 bp cBMP4 insert containing the entire open reading frame; Lane 2= lOObp size
ladder; Lane 3= High MW mass standard. Panel B shows the amplified cBMP4 insert
containing only the mature region of the cBMP4 DNA sequence. Lane 1= 354 bp
mcBMP4 insert containing the mature region (874bp-1227 bp) of the cBMP4 sequence;
Lane2= lOObp size ladder; Lane 3= Low MW mass standard.
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intact since the 28s, 18s and 5s rRNA bands were distinctive without degradation. The
RNA sample appeared relatively free of protein contamination since the
OD260nm/OD280nm ratio was 2.08.
PCR amplification ofcBMP4 entire coding region and mature region. A 1228bp
cBMP4 sequence was amplified from chick total RNA using RT-PCR (Figure 2A) and
ligated into Novagen's blunt end cloning vector pSTBlue-1 for storage in the long term.
In the mean time, mature cBMP4 was also amplified using 1228 bp cBMP4 PCR product
as template. The amplified mature cBMP4 insert with 354 bp length containing the
region from 874 bp-1227 bp of the cBMP4 sequence was indicated in Figure 2B.
Subcloning of mature cBMP4 gene into a mammalian cell expression vector. The
mature cBMP4 inserts were ligated into pretreated blunt ended expression vector
cDNA4/HisMax. After transformation of the constructed expression vector, cells grown
on the LA/AMP plates were selected to perform colony PCR using gene specific primers
in order to identify the colonies carrying the desired mcBMP4 insert. Gel analysis of
colony PCR products of individual E. coli clones indicated that all clones contained the
desired mcBMP4 inserts (Figure 3). In order to confirm the sequence and orientation of
the cBMP4 inserts, plasmids were isolated from three clones and sent out for DNA
sequencing.
A Blast search within the Genebank NCBI database confirmed the identity of the
inserted DNA sequence to be chick mature BMP4 and the mcBMP4 was ligated in the
correct orientation with the pcDNA/HisMax vector (Appendix 2).
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The partial DNA sequencing chromatogram of the pcDNA/HisMax-mcBMP4 construct
contained the first 24 bp of mature chick BMP4 sequence from nucleotide 287 to
nucleotide 310 (red underline) that ligated in frame with the enterokinase recognition
sites (yellow highlighted region). The arrow indicates the junction site between
mcBMP4 sequence and vector enterokinase recognition sequence, which further
indicated that the recombinant protein has the correct reading frame and orientation. The
DNA sequence (nucleotide 263 to nucleotide 286) underscored with blue dash line was
the Xpress Epitope, which can be recognized by anti-Xpress antibody to facilitate
recombinant protein identification (Figure 4). The full pcDNA/HisMax-mcBMP4
construct DNA sequencing chromatogram was indicated in the Appendix 3.
COS-7 cells transient expression condition optimization. COS-7 cells were
transfected transiently using pcDNA/HisMax/LacZ control vector at two different
Lipofectimin/DNA ratios (1:2.5 vs 1:3). In addition, the level of/3-galactosidase protein
expression was estimated using X-gal staining for five continuous days (Figure 5). /3galactosidase expression reached about 30% after 24 hour of transfection (Figure 5 A),
and then the maximum level of expression was achieved after 48 hours of transfection,
which was about 95% cells expressing /3-galactosidase (Figure 5 B). From day 3, protein
expression level decreased dramatically to about 20% (Figure 5 C), and almost
disappeared after day 4 (Figure 5 D-E). /3-galactosidase expression was not detected in
mock transfected cells (Figure 5 F). Because of the decline of protein expression after 48
hours, transient expression condition at two different Lipofectmine/DNA ratios was
optimized only at day two. There is no remarkable difference in terms of protein

34

12

3 4

5

6

7

8 9 10 11 12

354bp

Figure 3. Gel analysis of colony PCR products of individual E. coli clones
carrying the mcBMP4 insert. All clones contained the desired inserts.
pcDNA4/HisMax expression vector was used to clone mcBMP4 gene for
mcBMP4 expression in COS-7 cells. Colonies were boiled for 10 min and 10 JU.1
cell lysate were used for colony PCR. Lane 1= 100 bp DNA ladder; Lane3-12 =
PCR products of selected individual E. coli clones.
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Figure 4. Partial DNA sequencing chromatogram of pcDNA4/HisMaxmcBMP4 construct. Red underline: mcBMP4 DNA sequence; Yellow
highlight: EK recognition site; Blue dash line: Xpress epitope. Arrow
indicates the ligation site of mcBMP4 insert with the pcDNA4/HisMax
vector sequence.
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Figure 5. X-Gal staining of COS-7 cells to optimize transient expression
conditions. COS-7 cells were transfected transiently using pcDNAHisMax/LacZ
control vector and different Lipofectamine/DNA ratios. /3-gal expression was
monitored over 5 days. Panel A-E: cells expressing /3-gal from day 1 to day 5
post-transfection using a Lipofectamine/DNA ratio of 3:1; Panel F: mock
transfected cells without /3-gal expression. Panel G-H: Comparison of transient
transfection efficiency using two different Lipofectamine/DNA ratios at day 2.
Lipofectamine/DNA =2.5:l(PanelG). Lipofectamine/DNA =3:1 (Panel H).
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expression level by varying lipofectamine vs DNA ratio (Figure 5 G-H).
Lipofectamine/DNA ratio of 2.5:1 was chosen to conduct transfection using constructed
expression vector pCDNA4/HisMax_mcBMP4.
Mature cBMP4 protein expression and purification. After the transient
transfection condition had been optimized and the transfection efficiency verified by the
jS-gal staining assay, Cos-7 cells was transfected with the pcDNAhismax-mcBMP4
plasmid. Crude cell lysate was purified using the ProBond™ purification system, and
each elution fraction was examined for the presence of recombinant protein via Western
Blot (Figure 6). The predicted MW of mcBMP4 is about 12.8 KD, while the N terminal
peptide containing the Xpress epitope and the polyhistidine tag will add approximately
3.4 KD to the mcBMP4 protein. The total MW of the recombinant mcBMP4 protein is
thus approximately 16.2 KD. The western blot analysis showed that only the crude lysate
fraction (lane 1) and the flow-through fraction (lane 11) contained any detectable
recombinant mcBMP4 protein. No detectable recombinant protein was present
either in the wash fraction (lanes 2-4) or elution fraction (lanes 6-10).
Mature cBMP4 Protein Expression in E.coli
Subcloning of mature cBMP4 into a bacterial expression vector. Mature cBMP4
was also amplified using 1228 bp cBMP4 PCR product as template. The 370 bp mature
cBMP4 amplification product contained the region from 874 bp-1219 bp of the cBMP4
sequence and a linker region with BamHI sites (Figure 7). The mature cBMP4 insert was
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Figure 6. Detection of recombinant mcBMP4 protein expression in COS-7
cells using a 1:5000 dilution of anti-Xpress mAb by western blot.
Recombinant mcBMP4 was purified using a nickel chelating affinity column
and eluted with different concentrations of imidazole. Lane 1= crude lysate;
Lane 2-4= three individual wash fractions. Lane 5= MW standard; Lane 610= elution fraction with 50 mM, 200 mM, 300 mM and 500 mM imidazole
respectively. Lane 11= flow through fraction.

370 bp

Figure 7. Gel analysis of mcBMP4 inserts amplified by PCR from 1228 bp
cBMP4 DNA for cloning in pGEX-KG E.coli expression vector. Lane 1= 100 bp
DNA ladder; Lane 2 and lane 3= 370 bp amplified mcBMP4 inserts containing
Bam HI site for cloning in pGEX-KG vector.
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then ligated into the Bam HI digested E.coli expression vector pGEX-KG. After
transformation of the constructed expression vector, cells grown on the LA/AMP plates
were selected to perform colony PCR using gene specific primer in order to identify the
colonies carrying desirable mcBMP4 insert. From ten randomly selected clones, only
one clone (clone 10) contained the 370 bp mcBMP4 insert (Figure 8). In order to confirm
the identity and orientation of the mcBMP4 insert, pGEX-KG-mcBMP4 plasmids were
isolated and sequenced. Blast search within Genenbank confirmed the identity of the
inserted DNA sequence to be mcBMP4 and the mcBMP4 was ligated in the correct
orientation with the pGEX-KG vector (Appendix 4). The partial DNA sequencing
chromatogram of pGEX-KG-mcBMP4 construct indicated that the first 63 bp of the
mature chick BMP4 coding region (from nucleotide 874 to nucleotide 936, red underline )
was ligated in frame with the Bam HI linker site (yellow highlighted region) in the pGEX
Vector (Figure 9). The full pGEX-KG-mcBMP4 construct DNA sequencing
chromatogram was indicated in the Appendix 5.
Screening PGEX recombinants for fusion protein expression. Clone 10 was restreaked and five clones (Al through A5) were chosen as the potential candidates for
GST-mcBMP4 fusion protein screening assay. The predicted MW of mcBMP4 is about
12.8 KD, while the N- terminal peptide containing the GST protein tag and thrombin
cleavage site will add approximately 26 KD to the fusion GST-mcBMP4 protein. Thus
the predicted total MW of the recombinant mcBMP4 protein is approximately 40 KD.
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Figure 8. Gel analysis of colony PCR results obtained from individual E. coli
clones potentially carrying the mcBMP4 insert. One positive clone (lane 11) was
obtained. The pGEX-KG expression vector was used to clone mcBMP4 for use in
mcBMP4 expression in E. coli cells. Colonies were boiled for 10 min and 10 ul
cell lysate were used for colony PCR. Lane 1= 100 bp DNA ladder; Lane2-11 =
PCR products of selected individual E. coli clones.
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Figure 9. Partial DNA sequencing chromatogram of pGEX-KG-mcBMP4 construct.
Red underline: mcBMP4 sequence; Yellow highlight: Bam HI linker site. Arrow
indicates the ligation site of the mcBMP4 insert within the pGEX-KG vector
sequence.
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Figure 10. SDS-PAGE analysis ofE.coli clones in screening for GST-mcBMP4
fusion protein expression. Cells were grown in 2x YTA medium to reach an ODeoo
of 0.6-0.8, and induced using ImM IPTG for two hours. Crude cell lysate was
analyzed using 4-12% Bis-Tris NuPAGE gel in lx MOPs buffer, running at 200 V
for 50 min. The gel was stained overnight using Coomassie blue right after the
run. Lane 1=MW standards; Lane 2-6= cell lysate from selected individual clones.
Lane 7= cell lysate from pGEX-KG transfected control cells, confirming control
GST protein expression.

SDS-PAGE analysis of the five selected clones (lane 2-6) indicated that all five clones
contained the 40 KD fusion protein bands (Figure 10). Compare to other clones, clone
A4 (lane 4) demonstrated the highest level of protein expression. The control plasmid
(expression vector pGEX-KG without mcBMP4 insert) in the last lane produced a strong
GST protein band with expected molecular weight of 29 KD (26 KD GST protein plus
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3KD thrombin cleavage site). Besides the expected 40 KD fusion protein bands, a band
with approximately 66 KD was also observed for all the clones other than control. It is
possible that the 66KD band suggests a large conformation change upon dimerization of
mcBMP4 to form a tight insoluble or toxic aggregate. Alternatively, it is also possible
that some protein interactions present. The fact that more 66KD forms present in most of
these clones than the expected 40 KD monomeric fusion protein may suggest that
dimerization/aggregation or protein- protein association confers much greater protein
stability than is found when the protein is monomeric.
Fusion protein expression optimization. Optimization of the GST-mcBMP4
fusion protein production was investigated by varying IPTG concentration, growth and
induction temperature, and induction time. After optimization, a concentration of ImM
IPTG, an induction temperature of 37°C, and induction time of 2 hours were used for
subsequent inductions in 2x YTA medium.
Small scale protein purification. Small scale (100 ml) protein expression was
conducted under the optimal conditions listed above. GST-mcBMP4 fusion was
produced as a monomer with apparent MW around 40 KD. After thrombin cleavage, the
expression tag remained but the mcBMP4 was not detectable (Figure 11). Western
blotting further confirmed the expression of GST fusion protein using anti-GST
polyclonal antibody (Figure 12). In an effort to improve the protein yield, large scale (2
liter) protein expression was also conducted using Bugbuster lysis reagent supplemented
with PMSF. No significant improvement of the protein yield was observed (data not

42

1 2

3

4

5

6
IMP

3fe

MW(KD)
200
116.25

Wm
40KX)

97.4
66.2

^ ^

45
31
.flwtetiiHE

26KD

M

21.5
14.4

6.5
Figure 11. Coomassie-stained 4-12% Bis-Tris NuPAGE gel showing GST-mcBMP4
fusion protein expression in E.coli (2 hour induction at 37°C). Crude cell lysate was
purified using glutathione separose 4B affinity column and eluted with 10 mM
reduced glutathione. Gel was run at 200 V for 30 min in lx MES buffer. Lane 1=
crude cell lysate; Lane 2= flow through; Lane 3= pooled wash fraction; Lane
4=eluted fraction; Lane 5= eluted protein with GST tag removed after thrombin
treatment. Lane 6= MW STD.
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Figure 12. Detection of GST-mcBMP4 fusion protein expression in E. coli
using 1:1000 dilution of the anti-GST polyclonal antibody by western blot. Lane
1= crude cell lysate; Lane 2= eluted fraction; Lane 3= eluted protein with GST
tag removed after thrombin treatment.
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shown). The estimated protein concentration was approximately 15 (ig/ml. Total protein
yield is 300 mg in 2 L scale.
Monoclonal Antibody Production
Peptide selection. The selection of an antigenic peptide is the first and probably
the most critical step in the production of a monoclonal antibody. For a synthetic peptide
to be sufficiently antigenic, peptide selection should follow several principles. First, the
length of the peptide should be 6-25 amino acids long in order to form an immunogenic
epitope. It should be part of the mature protein, and mostly composed of hydrophilic
residues. Regions of proteins that are mostly composed of polar residues will be more
hydrophilic and are more likely to be exposed on the surface of the protein. It should be
accessible and not have residues that could be sites of glycosylation. Amino acids buried
inside an alpha helix or beta sheet will not elicit antibodies that recognize native protein.
Furthermore, for membrane spanning proteins, the peptide should not be within the
transmembrane domain, but should be present on the extracellular domain of the protein.
Finally, the desired peptide region should be specific and unique, and not have high
sequence homology with its close family members. In our project, therefore, only the
mature region of cBMP4 with low sequence homology with other BMP proteins was
chosen to be analyzed using Protean (DNASTAR, Madison).
The full length cBMP4 protein sequence with its potential glycosylation sites is
shown in Appendix 6. Multiple sequence alignment of BMP4 with its closest family
member BMP2 indicated that only the N- terminals of the BMP4 protein diverged
significantly in sequence homology when compared to BMP2, with the rest of the protein
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being highly conserved (Figure 13). It was also evident that the majority of the BMP4
residues at the N-terminals showed high sequence homology across other species, which
may indicate that it is likely that antibodies raised against the peptides selected from this
region may cross-react with other species.
BMP2_Mouse
BMP2_hm
BMP2_GG
BMP4_Mouse
BMP4_Hm
BMP4-GG

QAKHK--QRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFP
QAKHK--QRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFP
QAKHK--QRKRHKYSCKRHPLYVDFNDVGWNDWIVAPPGYSAFYCHGECPFP
SPKHHPQRSRKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP
SPKHHSQRARKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP
SPKHHG--SRKNKKNCRRHALYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP
**.
. . . *.** ***** ************** ******.****

BMP2_Mouse
BMP2_hm
BMP2_GG
BMP4_Mouse
BMP4_Hm
BMP4-GG

LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG
LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG
LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG
LADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKWLKNYQEMWEG
LADHLNS TNHAIVQTLVNS VNS SIPKACCVPTELSAISMLYLDE YDKWLKNYQEMWEG
LADHLNSTNHAIVQTLVNSVNSSI PKACCVPTELSAI SMLYLDEYDKWLKNYQEMWEG
********************** ********************* .********.*****

BMP2_Mouse
BMP2_hm
BMP2_GG
BMP4_Mouse
BMP4_Hm
BMP4-GG

CGCR
CGCR
CGCR
CGCR
CGCR
CGCR

****

Figure 13. Multiple sequence alignment of mature BMP 4 sequence with BMP2
sequence across the species. Blue (*) identical residue. Green (:) structurally
conserved residue.

Four aspects of the mcBMP4 peptide sequence were analyzed using the Protean function
of the Lasergene software: secondary structure, hydrophilicity, antigenicity and
accessibility (Figure 14). The Lasergene software uses the original method of Chou and
Fasman to predict helices, sheets, and turns (Chou & Fasman, 1978). The secondary
structure of BMP4 was also predicted according to a slightly modified method of Gamier
- Robson (Gamier, Osguthorpe, & Robson, 1993). Hydrophilicity is calculated according
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to the algorithm of Kyte and Doolittle (Kyte & Doolittle, 1992). They evaluated the
hydrophilic and hydrophobic tendencies of the sequence. This profile was useful for
predicting exterior vs. interior regions of the native protein. Surface probability was
calculated according to the formula of Emini (Emini, Hughes, Perlow, & Boger, 1985).
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Figure 14. BMP4 antigentic peptide selection using Protean. Four aspects of
the peptide sequenced were analyzed: secondary structure, hydrophilicity,
antigenicity and accessibility.
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The antigenic index (AI) is a measure of the probability that a region is antigenic.
It is calculated by summing several weighted measures of secondary structure (Jameson
& Wolf, 1988). The outputs of peptide prediction were indicated in Figure 14. The Nterminal sequence (residue 1-20) was predicted to be highly hydrophilic, accessible and
antigenic with very little alpha helix or beta sheet structure. Together with the multiple
sequence alignment results, one peptide sequence (SPKHHGSRXNKKNCRRH) with a
total of 17 residues was selected for peptide synthesis.
Screening assay optimization. The dilution of the primary and secondary
antibody was optimized using ELISA for use in a screening assay. The dilution of
primary antibody was started as 1:20, and then a series of two fold dilution was made.
The dilution of secondary antibody was started at 1:500. In general, the mice immune
response to cBMP4-KLH conjugates was very weak and no reaction was detectable when
the immune serum's dilution was higher than 1: 40. The absorbance (405 nm) values of
the immune serum (red bar) were considerably higher than those of the pre-immune
serum (yellow bar) when assayed using a 1: 500 dilution of the secondary antibody
(Figure 15). Primary antiserum dilution of 1: 20 and secondary antibody dilution of 1:
500 were chosen to further analyze the immunogenicity of BMP4 peptide.
The amount of peptide (500 ng to 7.8 ng) to coat the ELISA plates was also
optimized and evaluated using three pooled immune serum dilutions (Figure 16). The
higher the immune serum dilution, the lower the absorbance value was expected.
However, the higher the amount of antigen coating the plate, the lower the absorbance
intensity was found for each dilution. It seemed that the peptides were present in the
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Figure 15. ELISA analysis using different secondary antibody dilutions. Absorbance
(405nm) values of anti-cBMP4 immune serum at different secondary antibody dilutions.
ELISA plates were coated with 1 |ig synthetic cBMP4 peptide and incubated with serial
dilutions of pooled mice immune serum. A serial dilution of the primary Ab was tested
at two different HRP conjugated secondary antibody concentrations.
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Figure 16. ELISA analysis using different amounts of cBMP4 peptide antigen.
Absorbance (405nm) values of samples containing different amounts of synthetic cBMP4
peptide antigen (7.8-500 ng) reacted with three dilutions of pooled immune serum in
ELISA using 1:500 dilution of HRP conjugated rabbit anti-mouse secondary antibody.
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appropriate conformation without overlapping on each other only when small amount of
peptide was used to coat the plates. The highest absorbance detected using 7.8 ng peptide
was used to coat the plates.
Immune serum specificity was evaluated by competitive ELISA. Three immune
serum dilutions were made and pre-absorbed with 500ng cBMP4 antigenic peptide for an
hour. The mice immune response to cMBP4 peptide was specific since immune serum
had higher absorbance value than that of pre- absorbed immune serum at all three
different dilutions, especially at the highest immune serum dilution (1:80). As we
expected, the antibody produced is specific since the higher the antibody dilution, the
lower the amount of antibody would present after it was pre-absorbed with the antigen,
and therefore, the lower the absorbance (Figure 17).
Monoclonal antibody production. The mouse immune response to the antigenic
peptide was weak, and no hybridomas secreting specific antibody were detected (data not
shown). Monoclonal antibody production was discontinued.
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Figure 17. Competitive ELISA analysis. Absorbance (405nm) values of
samples containing different amounts of synthetic cBMP4 peptide antigen (7.8500 ng) reacted with three dilutions of pooled immune serum or pre-absorbed
immune serum in competitive ELISA using 1:500 dilution of HRP conjugated
rabbit anti-mouse secondary antibody. The pre-absorbed immune serum was
prepared by incubation with 500ng cBMP peptide for one hour before adding to
the ELISA plates.
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Discussion
Cardiac septation defects and valve malformation are the most common
congenital birth defects. Recently, congenital heart malformation studies using mouse
and chick models have revealed critical yet still poorly understood roles of BMP4 in
cardiogenesis. BMP4, for example, appears to be involved both in EMT formation and
apoptosis in both endocardial cushions and ventricular myocardium during embryo
cardiogenesis (Zhao & Rivkees, 2000). BMP4 has also been identified as a signaling cue
from myocardium directly mediating atrioventricular septation (Jiao et al., 2003). Defects
in this process cause one of the most common human congenital heart abnormalities,
atrioventricular canal defect, but the role of BMP4 in septum formation remains unclear.
In order to further explore potential roles of BMP4 during embryonic heart development,
time course studies mapping BMP4 mRNA expression patterns have recently been done
using in situ hybridization (Somi et al., 2004). These expression studies, however, are
still incomplete with respect to the stages of development examined and the specific
regions of the heart investigated. Moreover, the BMP4 mRNA expression patterns may
not necessarily represent BMP 4 protein expression and final deposition patterns. BMP4
is, after all, a secreted protein, and identifying where its origin will not necessarily reveal
its field of deposition within the tissue nor its domain of action. Unfortunately, so far
only one published paper has focused on immunolocalization of BMP4 protein to
examine its expression domain in the development of embryonic endocardial cushions. It

is absolutely critical, therefore, to further examine BMP4 protein expression patterns to
facilitate our understanding of its function in embryonic heart development.
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We selected the chick as research model to carry out a time course study on
BMP4 protein expression, although the mouse is often preferred (since it is more closely
related to humans than are avians). There are, however, many inherent and practical
drawbacks to the use of the mouse as a model organism as opposed to the chick,
including much higher animal care/housing expenses, more restrictive regulations
regarding the use of mice in animal research, inaccessibility of the embryos during
development (and thus an inability to assess the developmental stage of the embryo prior
to harvest and an inability to carry out any surgical manipulation, viral transfection or
microinjection), the fact that adult animals need to be sacrificed to obtain embryos, the
longer gestation time relative to the chick. Like the mouse, the chick too possesses a four
chambered heart and a circulatory system extremely similar to that of the human, with a
high degree of conservation in structural and regulatory genes. Finally, chick embryos
have been extensively studied by embryologists for 100 years, and many developmental
stages have a number of well-defined anatomical markers that aid in staging of the
embryos.
To localize BMP4 protein expression domains during early embryonic
cardiogenesis, a specific, high affinity antibody would prove an invaluable tool, and the
homogeneity of antibody isotype, antigenic (epitope) specificity, consistent titer etc
exhibited by a monoclonal antibody would be particularly beneficial. Despite the clear
utility of such a reagent, however, anti-chick BMP4 antibody is still not commercially
available, and the cross-reactivity between anti-human BMP4 mAbs (which are available)
against chick BMP4 remains untested by any of the antibody manufactory companies
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contacted so far. The short-term goal of this project then was the production of BMP4
protein for use as an immunogen in the generation of a BMP4 mAb. Producing a mAb
using a synthetic BMP4 peptide was also sought simultaneously since this approach
might succeed in generating a mAb without waiting for large amounts of BMP4 to be
purified.
There are three commonly used approaches for monoclonal antibody production
based on the different nature of the immunogen: (i) production using natural proteins, (ii)
production using recombinant proteins, and (iii) production using one or more synthetic
peptides that correspond to specific regions of the native immunogen. Natural proteins
are perhaps the ideal immunogens, providing sequence-specific and surface structural
epitopes. Natural proteins such as BMP4, however, are often expressed in small amounts.
Early attempts to extract BMP protein from bovine bone powder indicated that only 40
jag of protein could be obtained from 40 kg quantities of bovine bone powder (Wozney et
al., 1988). Obtaining adequate amounts of BMP4 from chick embryos as immunogen,
therefore, is most likely impractical, since it will probably require excessive amounts of
embryos as starting material.
Recombinant fusion proteins produced in mammalian cells or bacteria are also
used successfully to produce antibodies recognizing specific, three-dimensional
determinants. We also adoped this approach, choosing to express a mature cBMP4
fusion protein in both mammalian cells and bacteria cells. Ideally, such an approach
would produce enough protein both for use as an immunogen in the production of a mAb
and for hybridoma screening purposes.
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As a third approach, synthetic peptides conjugated to carrier proteins can
sometimes be used to generate antibodies. Although the cost of peptide synthesis is high
and the antibody ultimately produced may not recognize the native protein, the
advantages of the approach are significant. First, the investigator can, using various
bioinformatics tools, design a peptide from a region of the protein that is unique to that
protein (especially useful when the protein is one member of a large class of structurally
related family members). Secondly, the synthetic peptide can be made easily and quickly,
allowing immunization to be started right away. Third, the protein domain recognized by
the antibody is unambiguously defined, allowing its use in structural antigen mapping
studies. Finally, the defined nature of the immunogen allows the immunogenic peptide to
be used later as a blocking peptide, a very valuable reagent when trying to prove
specificity of binding. Considering the time frame of this project and the intrinsic
difficulty of recombinant protein production, the use of a synthetic peptide was deemed a
viable approach for antibody production, and worth an effort despite its disadvantages.
Recombinant Protein Expression in Mammalian Cells
Mammalian cells are commonly used for production of recombinant proteins,
especially those of vertebrate origin. In contrast to lower eukaryotes or prokaryotes,
mammalian cells possess the appropriate protein processing machinery and often provide
active recombinant proteins that possess important post-translational modifications
(glycosylation, phosphorylation, proteolytic modification, etc.) required for in vivo
function. Stable expression technologies, based on chromosome-integrated plasmid
sequences and amplifiable expression cassettes such as the dihydrofolate reductase or
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glutamine synthetase system, have been shown to provide high levels of recombinant
protein expression up to the grams-to-kilograms scale. There are, however, several
disadvantages associated with stable expression systems. Development of stable cell
lines requires a considerable investment in time, expensive additional reagents (especially
selection antibiotics), human resources and lab equipment. In contrast, transient
expression provides an economic alternative approach for protein production in the
milligram-to-gram scale, which is more suitable for small-scale research purposes.
In order to get proper folding protein with bioactivity, the best approach for
recombinant protein production is to produce native cBMP4. Due to intrinsic difficulties
in cloning the entire coding region of BMP4, however, the mature region of BMP4 was
selected instead. Masuhara et al. (1995) found that homodimeric protein can be used to
produce monoclonal antibody that can also recognize the native dimeric BMP protein. In
this study, the mature region of chick BMP4 was cloned into the mammalian expression
vector pcDNA4 /HisMax, and then transiently expressed in COS-7 cells. The fusion
mcBMP4 was apparently produced as a monomeric protein with molecular weight about
16.2 KD as shown by western blotting, suggesting that the disulfide bond was not linked
through the seventh cystine residue intermolecularly to form the BMP4 homodimer (as
opposed to native BMP4) although mammalian cells should provide all the machinery
necessary for protein dimerization. One possible explanation of this phenomenon is that
either the absence of both the signal peptide and the prodomain of the BMP4 or the
addition of the N-terminal fusion tag may greatly impact the BMP4 protein processing
and trafficking in the mammalian cells, with the result that the protein dimmer is not
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formed effectively. It is also possible that without the prodomain, the recombinant
BMP4 protein is not folded in the correct conformation, in turn causing misalignment of
the critical cystein residues and thereby preventing formation of the homodimer. The
fusion protein was folded in such a way that the binding of the purification tag (especially
the 6-histidine residue) to the nickel-chelating column was prevented. The fact that
mcBMP4 was only present in the crude cell lysates and the nickel affinity column flowthrough fraction during protein purification (instead of column elution fractions as
expected) tends to support this hypothesis.
Besides the problem associated with protein misfolding, the level of fusion
protein expression was low. No strong bands with expected molecular weight of 16.2KD
were detected in the SDS-PAGE gels following staining by Coomassie Blue. To further
explore the reasons underlying this low level of expression, three key features critical to
optimal small scale transient transfection and recombinant protein expression in
mammalian cells were evaluated: (i) the nature of the host cells, (ii) the nature of the
expression vector, and (iii) the nature of the transfection system.
i) Host Cells. Three cell types have been the most popular for transient
recombinant protein expression: human embryonic kidney (HEK)-293 cells, COS cells
and baby hamster kidney (BHK) cells. Interestingly, although CHO cells (the most
widely used host for stable recombinant protein expression) are more frequently used for
recombinant BMP protein expression, they have failed so far to give satisfying

expression levels when transfected transiently (Wurm & Bernard, 1999). Like CHO,
COS cells are routinely grown as adherent cultures, can be grown to fairly high density,
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can be adapted to a variety of growth media etc. Human recombinant BMP4 was first
transiently expressed in COS-1 cells to determine the in vivo activities of the BMP
polypeptides (Wozney et al., 1988). Fifteen years later, another BMP family member
structurally similar to BMP4 (human recombinant BMP7) was successfully produced as a
mature, disulfide-linked, biologically active homodimer in COS-7 cells (Lee et al., 2003).
Those studies supported the idea that at least some clones of COS cells could serve as a
functional host for recombinant BMP4 expression, and served as a major justification for
our selection of COS-7 cells in this study. The COS-7 cell is an African green monkey
kidney fibroblast-like cell line suitable (like most other COS cell lines) for transfection
by vectors requiring expression of SV40 T antigen, and will allow episomal amplification
of plasmids containing a SV40 origin of replication. The use of such plasmids as
expression vectors, therefore, would be expected to increase recombinant protein
expression levels by permitting more plasmid copies to persist in the transfected cells
throughout the production phase (Van craenenbroeck, Vanhoenacker, & Haegeman,
2000).
ii) Expression vector. There are many expression vectors available commercially.
One important issue for high level recombinant protein expression is to use vectors with
promoters that are highly active in the host cell line chosen. One example of such a
strong, constitutively active promoter active in COS cells is that adapted from the human
cytomegalovirus (CMV). Plasmids that carry an SV40 origin of replication will also

enable vector replication in COS cells (which constitutively produce the SV40 T antigen
required for SV40 genome replication), thereby increasing the plasmid copy number and
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thus the transcriptional capacity for recombinant protein production. Another big
consideration in vector choice is the presence of structural modification cassettes (which
encode protein purification motifs or tags) and the ease with which those modifications to
the recombinant protein will facilitate downstream purification. The pcDNA4/HisMax
vector from Invitrogen was selected because it carries a CMV promoter, possesses an
SV40 origin of replication and produces a recombinant 6-His tagged protein, allowing
convenient and efficient metal-chelation affinity purification. It is instructive to note, for
example, that the pcDNA3.1/HisMyc vector (which possesses a backbone essentially
identical to that of pcDNA4/HisMax) was able to replicate up to 10,000 copies in cells
expressing large T antigen (Chittenden, Frey, & Levine, 1991). Besides high copy
number, our vector also contains a QBI SP 163 translational enhancer, which increases
expression of recombinant protein via a cap-independent translation mechanism. Other
useful features of this vector include the presence of the Xpress epitope (which can
facilitate protein detection in vivo) and the presence of an Enterokinase cleavage site
(which allows removal of N- terminal tag from to create the native protein).
iii) Transfection system. The transfection system is another important factor to
consider about because it is related to gene transfer efficacy. There are many highly
effective gene transfer reagents and methodologies commercially available: (a) the
DEAE-dextran method, (b) the calcium-phosphate method, (c) electroporation, (d)
ballistic methods, (e) transfection using recombinant viruses, and (f) lipid and liposomemediated transfection. DEAE-dextran was one of the first chemical reagents used for
transfer of nucleic acids into cultured mammalian cells. DEAE-dextran is a cationic
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polymer that associates with negatively charged nucleic acid. The positive charged
polymer enables the DNA polymer complex to come into closer association with the
negatively charged cell membrane, ultimately facilitating uptake into the cells by
endocytosis.
Calcium phosphate co-precipitation is also widely used for transfection. Mixing
DNA with calcium chloride in PBS will allow the mixture to precipitate and disperse on
to the cultured cells. The precipitates can then be taken up by the cells via endocytosis or
phogocytosis. This method is widely used because the components are easily available
and reasonable in price, but the transfection efficiency is low with low reproducibility.
Electroporation is one of the physical methods for gene transfer. The mechanism
for entry into the cell is based upon perturbation of the cell membrane by an electrical
pulse, which forms pores that allow the passage of nucleic acids into the cell. Although
high transfection efficiency can be achieved using electroporation, the technique requires
an expensive electroporator and the cell mortality is high. In addition, fine-tuning and
optimization for duration and strength of the pulse for each type of cell are critical to
achieve a fine balance between conditions that allow efficient delivery and conditions
that kill cells.
Liposome mediated delivery has been widely used to deliver DNA into cells.
Unlike the DEAE-dextran or calcium phoshate chemical methods, liposome mediated
nucleic acid delivery can be used for in vivo transfer of DNA and RNA to animals and
humans. Invitrogen's Lipofectamine 2000 is one of many cationic lipid-based
transfection reagents presently on the market. Lipofectamine is formulated to give high
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transfection efficiency with little toxicity to cells. Invitrogen claims that this reagent
gives the highest protein expression levels in the widest variety of adherent and
suspension mammalian cell lines compared to similar products. Researchers found that
greater than 90% efficiency can be achieved consistently for use lipofectamine to
transfect a range of cell lines such as HEK-293, CHO and COS-7. Lipofectamine 2000
was used as the transfection agent in this study and it indeed showed very high
transfection efficiency (more than 95%).
In this study, the design of the mammalian expression system was carefully
weighed against the basic criteria discussed above. Since the low expression level does
not appear to be due to the cell line, expression vector or transfection method, the
possibility that low protein expression is largely dependent on the nature of the protein
must be considered. In fact, a previous study also showed that the transient expression
level of BMP proteins were found very low in COS cells. In that study, the level of
expression was dependent on the individual BMP being expressed, but in the best case
there was less than 1 percent of the total protein produced (Wozney et al., 1988).
Another explanation for the observed low protein expression may be protein misfolding,
with the misfolded protein perhaps being targeted for lysozomal degradation.
Recombinant Protein Expression in E. Coli
Relative to mammalian cells, expression in E. coli is simple and inexpensive.
Because of the difficulties encountered in producing large amounts of mcBMP4 in
mammalian cells (and associated protein purification problems discussed in the above
section), as an alternative approach, expression of mcBMP4 in a bacterial system (E. coli,
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BL-21 strain) was attempted to produce sufficient protein for immunization. Monomeric
mouse mature BMP4 produced in E. coli might elicit the production of a monoclonal
antibody that could recognize the native dimeric BMP protein.
E. coli is a gram-negative bacterium containing two membranes: (i) an inner
membrane separating the cytoplasm from the periplasm, and (ii) an outer membrane to
protect the bacterium from the surrounding environment. The heterologous protein
expressed in E. coli cells can be directed to the reducing cytoplasm or the comparatively
oxidizing periplasm, which facilitates disulfide bond formation. Although for
heterogeneous protein composed of several disulfide bonds, periplasm expression is an
ideal choice, one inherent drawback of targeting protein secretion to the periplasm is that
poor secretion of protein across the inner membrane will result in low protein yield upon
purification. As a secondary consequence of impeded protein transport across the plasma
membrane, accumulation of the recombinant protein in the periplasm can sometimes
produce significant cytotoxicity. For that reason, heterologous protein is often targeted in
cytoplasm.
In this study, the recombinant GST-mcBMP4 protein yield was relatively low,
possibly due to low protein solubility. Although the production of recombinant fusion
proteins in E. coli is a well- established technology, some of these factors that may limit
production and purification of soluble fusion proteins include: (i) host strains, (ii) the
nature of the expression vector, (iii) growth conditions encountered by the recombinant
organism, and (iv) the conditions used to induce recombinant protein synthesis.

61

i) Host strain. A wide variety of E. coli host strains can be used for cloning and
expressing recombinant protein. Strains deficient in known cytoplasmic protease gene
products, such as Lon, OmpT, DegP or HtpR may aid in the expression of fusion proteins
by minimizing the effects of proteolytic degradation by the host. An example of such a
host strain is E. coli BL-21, a strain defective in OmpT and Lon protease production. BL21 is a well-established strain proved to be able to express the fusion protein in a soluble,
intact form. In our project, BL-21 strain was used for cBMP4 protein expression.
ii) Expression vector. A glutathione S-transferase (GST) based gene fusion and
expression vector, pGEX-KG, was generously provided by Dr. Julio Soto (whose
laboratory routinely uses this vector for recombinant protein expression). This vector is a
versatile system for the expression, purification, and detection of fusion proteins
produced in E. coli, and is based on inducible, high-level expression of a gene (or gene
fragment) fused in frame with the Schistosoma japonicum GST coding region.
Expression in E. coli yields fusion proteins with the GST moiety at the amino terminus
and the protein of interest at the carboxyl terminus. Expression is under the control of the
tac promoter, which is induced by the lactose analog IPTG. All pGEX vectors are also
engineered with an internal taclq gene, the product of which is a repressor protein that
binds to the operator region of the tac promoter to prevent expression until induction by
IPTG, thus maintaining tight control over expression of the insert. In addition to offering
chemically inducible, high-level expression, the vectors allow mild elution conditions for
release of fusion proteins from the affinity medium. The protein produced would
accumulate within the cell's cytoplasm.
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iii) Growth conditions encountered by the recombinant organism. Growth
parameters are critical in regulating the yield of non-degraded fusion protein. Important
variables include growth temperature, duration of the induction period, degree of culture
aeration and cell density, the optimization of which often requires striking a balance
between yield and quality of the desired recombinant protein. Low temperature growth
conditions, for example, can sometimes minimize protein misfolding. This, in turn, will
increase protein quality (where properly folded protein is considered to be of higher
quality). Since properly folded protein tends to be more soluble, such growth conditions
also tend to minimize protein aggregation, increasing potential recovery and yield. Cells
grow much slower, however, at reduced temperatures. The decreased cell density tends
to reduce the yield. In this experiment, due to time, expense and cell culture system
limitations, growth temperatures below 30°C, changes in aeration, nutrient
supplementation during induction, etc. were not tested. We found cultured cells at 30°C
resulted in no significant improvement of protein quality or yield.
iv) The conditions used to induce recombinant protein synthesis. Many
heterogeneous proteins fail to fold into their native state when overexpressed in E.coli.
Instead, they are either degraded by the cellular proteolytic machinery or accumulated in
insoluble form, typically as inclusion bodies. Inclusion bodies are large in size, resist
proteolysis and hence can be easy to purify from other cellular components. Purified,
insoluble inclusion bodies can be solubilized under strong denaturing conditions such as
8 M urea or 6 M gauanidium chloride, and removal of denaturants sometimes allows
refolding of the denatured protein. Unfortunately, the best conditions for refolding are
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empirically determined from a set of general guidelines for refolding (Buchner &
Rudolph, 1991J and can be painstaking to perform. Optimizing inducing conditions
could also potentially increase protein yield through increasing protein solubility. The
inducing conditions include varying the concentration of IPTG and duration of the
induction time. We observed that varying IPTG induction conditions (0.1 mM to 1 mM
IPTG) or duration of the induction time made no significant difference in protein
solubility or yield.
Monoclonal Antibody Production
We designed and obtained synthetic peptides for use in immunizing mice for
antibody production. This approach, however, did not prove successful. The mouse
immune response to the peptides was very low, producing antisera with only weak
immunoreactivity (maximum immune serum titer reached a value of only 80). Due to the
low immune response, the hybridomas we obtained following fusion were incapable of
producing antibodies of any significant titer against BMP4. Factors that could contribute
to low mouse immune responses included: i) choice of host, ii) peptide selection, iii)
selecting the protein carrier and iv) coupling strategy.
i) Choice of host. The animal chosen for immunization should be genetically very
different from the animal chosen as the source of the immunogen. In order to achieve a
maximum immune response, it is important to avoid self-recognition of the immunogen
by the host animal. Although selection of mouse as the host to produce anti-chick BMP4
antibody seems to be a good choice, there is a large homogeneity of BMP4 across the
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species. Thus the mouse may have some self-tolerance for this protein, which may
contribute to the low immune response.
ii) Peptide selection. There are several elements that may impact the antigenicity
of the peptide. First, the selected region should be unique. The region of the peptide
selected should be from the mature region, should not possess a site of glycosylation and
should represent a unique sequence that would help ensure specificity to the target
protein. Second, the peptide should be hydrophilic, flexible and accessible. Since most
naturally occurring proteins in aqueous solutions have their hydrophilic residues on the
surface and their hydrophobic residues buried in the interior, the selected peptide should
be hydrophilic, surface oriented and flexible in order to produce antibody recognize the
native protein. The highest point of average hydrophilic for a series of contiguous
residues is usually at or near an antigenic determinant (Hopp & Woods, 1981). Because
the C-termini or N -termini of proteins are often exposed and have a high degree of
flexibility, they are usually a good choice for generating anti-peptide antibodies directed
against the intact protein. In our case, the peptide we selected is located in the Nterminal with high accessibility, hydrophilicity and flexibility. Third, the structure of the
peptide should be accessible. If the 3D structure of the protein is known, this can greatly
assist in choosing exposed epitopes. Surface regions or regions of high accessibility
often border helical or extended secondary structure regions. In addition, sequence
regions with beta-turns or amphipthic helix character have been found to be antigenic
(Parker & Hodges, 1991). Fourth, the length of the peptide should be appropriate. There
are two different thoughts on the topic of peptide length. One suggests that long peptides
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(20-40 amino acids in length) are optimal because it increases the number of possible
epitopes. The other suggests that smaller peptides are sufficient, and their use ensures
that the site-specific character of anti-peptide antibodies is retained. Any peptide selected
must be chemically synthesizable and should be soluble in aqueous buffer for conjugation
to carrier proteins. Peptides longer than 20 residues in length are often more difficult to
synthesize with high purity because there is greater potential for side reactions, and they
are likely to contain deletion sequences. On the other hand, short peptides (<10 amino
acids) may generate antibodies that cannot recognize the native protein. The typical
length for generating anti-peptide antibodies is in the range of 10-20 residues. Peptide
sequences of this length minimize synthesis problems, are reasonably soluble in aqueous
solution and may have some degree of secondary structure. The peptide length we
selected is within this range.
iii) Selecting the protein carrier. Conjugation to a carrier protein is important
because peptides are small molecules and do not tend to be immunogenic. The carrier
protein contains many epitopes that stimulate T helper cells, which helps induce the B
cell response. Many different carrier proteins can be used for coupling to synthetic
peptides. The most commonly selected carriers are keyhole limpet hemacyanin (KLH)
and bovine serum albumin (BSA). The higher immunogenicity of KLH often makes it
the preferred choice. Another advantage of choosing KLH over BSA is that BSA is used
as a blocking agent in many experimental assays. KLH was used for conjugation in our
project.
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iv) Coupling strategy. The coupling site and technique utilized also play
important roles in determining the reactivity of the antibodies. Generally, peptides can be
coupled to other proteins by utilizing: a) A free NH2 or COOH (recommended for
peptide when Cysteine cannot be added to the peptides); b) A free Cysteine group
(available as part of the sequence or added at the N or C-terminus). The coupling method
utilized in our project was Glutaraldehyde method, which is empirically selected based
on the recommendation of the peptide synthesis scientist at ADI International.
Glutaraldehyde is a bifunctional coupling reagent that links two compounds through their
amino groups. Glutaraldehyde provides a highly flexible spacer between the peptide and
carrier protein for favorable presentation to the immune system. Unfortunately,
glutaraldehyde is a very reactive compound and will react with Cysteine, Tyrosine and
Histidine to a limited extent. The result can be a poorly defined conjugate. The
glutaraldehyde method is particularly useful when a peptide contains only a single free
amino group at its amino terminus. If the peptide contains more than one free amino
group, large multimeric complexes can be formed, which are not well defined, but are
highly immunogenic.
Although the selected cBMP4 peptide meets all these criteria, immunogenic
capacity of a peptide not only depends on intrinsic chemical properties of the peptide but
also on extrinsic factors such as the host immunoglobulin repertoire, self-tolerance and
various cellular and regulatory mechanisms definable only in the context of the host (Van
Regenmortel, 2001). A strong humoral immune response directed against the peptide is
thought to require the stimulation of two cell types. Specific pre-B lymphocytes must be
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stimulated by the binding of the peptides to their immunoglobulin receptors. These cells
mature into the antibody secreting lymphocytes. A strong response also requires the
stimulation of helper T lymphocytes by the interaction of the carrier portion of the
peptide-carrier complex with the appropriate T lymphocyte cell surface receptor. Thus,
an effective immune response will largely depend on the interaction of peptide carrier
with both B cells and T cells. The immunogenicity of a peptide is not completely
understood, but low mice immune response may be influenced by several uncontrollable
factors in the host such as accessibility to binding by the B cell surface receptors, ability
of the carrier to stimulate helper T cell production, stability of the immunogen with
respect to macrophage degradation and presentation to the immunes system, size of the
reacting B and T cell populations, etc. (Shinnick, Sutcliffe, Green, & Lerner, 1983).
Future Directions
This study has shown that recombinant mature chick BMP4 (mcBMP4) can be
expressed in both COS-7 cells and E. coli cells, but at levels too low to be of any
practical use for the production of immunogenic protein and monoclonal antibody
generation. It was unsuccessful to express mature BMP4 protein a monomer. Producing
correctly folded mcBMP4 protein may require cloning and expressing of a full length
BMP4 pre-protein. In that case, firstly, it would be necessary to redesign both the PCR
primers (to include restriction enzyme sites for oriented cloning) and the expression
vector (to allow production of a fusion protein carrying a C-terminal tag immediately
downstream of an enterokinase site). The vector modifications would hopefully allow
proper folding of the BMP4 precursor and subsequent proteolytic processing of the pre-
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protein into a mature disulfide-linked BMP4 dimer. Ideally, such folding and proteolytic
processing would occur normally for the recombinant BMP4 fusion protein despite the
presence of the C-terminal purification tag (His domain, GST domain, etc.). If it was
later decided to remove the tag, the presence of the enterokinase cleavage site would
facilitate this effort. The stop codon at the end of the chick BMP4 DNA coding
sequence, for example, would need to be altered (using site directed mutagenesis) in
order to allow expression of cBMP4 with fusion tag at the end.
Secondly, given the known processing requirements and their apparent necessity
for protein stability, expression in eukaryotic cells will be required. Switching the
position of the tag to the C-terminal end would also facilitate inclusion of the secretion
signal at the N-terminus. In order to improve the protein yield, generation of a stable
expression cell line might be a reasonable alternative to transient expression, especially
considering the low expression level observed with the current construct. Finally, the cell
line selected for stable expression could be adapted for suspension culture since the
culture volume can be easily expanded prior to use in protein purification. This would
facilitate starting from a greater initial number of cells and aid in the isolation of more
BMP4 protein.
The use of synthetic peptides as immunogens for monoclonal antibody production
should be pursued using a combination of two or more peptides together to immunize
mice, stimulating a stronger immune response than a single peptide. At least one peptide

should be selected from the unique region of the cBMP4 protein, and the others could be
selected from evolutionary conserved regions of the cBMP4. Any hybridomas resulting
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from this immunization strategy should be screened against the unique region antigenic
peptide to minimize the possibility of selecting mAbs that recognize the conserved
region. Efforts to design two or three such immunogenic peptides are currently
underway.
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Appendix 1. IACUC approval of using mice for monoclonal antibody production.

San Jose State University
Institutional Animal Care and Use Committee
LETTER OF OFFICIAL PROTOCOL REVIEW
Date; November 1 7, 2006
Dear Dr. White
The animal care and use portion of your research proposal indicated below was reviewed
by the Institutional Animal Care and Use Committee (IACUC). The status of your
proposal is as follows:
Principal Investigator(s): Steven White, Sherry Li
Protocol #: 867
Title: Production of Monoclonal Antibody to Detect Bone Morphogcnetic
Protein (BMP4) Expression Domain During Chick H e a r t
Development.
The application was approved without modification by the IACUC
Approval date: J u n e 1,2005

*

Expiration Date: May 3 1 . 2007

The IACUC must be informed in writing of any proposed changes to the approved
protocol outline and approval must be granted in writing by the IACUC before any
change is instituted. If you wish to continue the approved outline beyond the expiration
date listed, it is required that you submit a request for protocol approval extension for
IACUC consideration in April 2007.
The protocol number (#867) may only be used by the principal investigator and
participants included on the approved application form. I'he protocol number will be
required to order animals (maximum of 9 mice and 24 fertile chicken eggs) and be
included on grant or contract proposals to lhn<\ the project. Please notify the UAC office
for placing animal orders or to request the transfer of live animals to or from this
approved protocol.
If you iiave any questions, feel free to contact, me at 408-924-4929.
^ytA/V-"-* 1

£

I'liis protocol lias lH'i'ii approved as II lli-ullli
Kisk C'ali-uiiryOiic l i \ e l project (I(C'-I).

Larry Young, RvjT, L A J g
IACUC Coordinator

I'lcusc ri'li'r lo the ;illiiclu(l risk c:i(C(ior\
ilosci'iption psi^e for relet mil pci MIIIIICI
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Appendix 2. Verification of mcBMP4 insert identify and orientation in pcDNA4/HisMax
mammalian expression vector by BLAST search.
Gallus gallus bone morphogenetic protein 4 (BMP4), mRNA
Score = 654 bits (354), Expect = 0.0
Identities = 354/354 (100%), Gaps = 0/354 (0%)
Strand=Plus/Plus
Query

287

AGCCCCAAGCACCACGGTTCCCGCAAGAACaaaaaaaaCTGCCGCCGCCACGCTCTCTAT

346

IIIIIIIIIIIIIIMIIIIIMMIIIIIIIIIIIIIIIIIIIMIMIIIIIMIMI
Sbjct

874

AGCCCCAAGCACCACGGTTCCCGCAAGAACAAAAAAAACTGCCGCCGCCACGCTCTCTAT

933

Query

34 7

GTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGcccccccGGGCTACCAGGCG

4 06

IlilllllllllllllllllllillllllllilllillllllllllilllMMMIIII
Sbjct

934

GTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGCG

993

Query

4 07

TTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCAC

4 66

lillllllllMIIMIilllllllllMMIIIIIIIilMlllllllllilillllll
Sbjct

994

TTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCAC

1053

Query

467

GCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGTG

526

MIIIIIIIIIMIIIMIIIIIIMMIMIIIIIIIIIIIIIMIIIIIIIMIilM
Sbjct

1054

GCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGTG

1113

Query

527

CCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCTG

586

IIMIIIIMIIIMIIIIIIIIIIMIIilMlllilMMIilllllllllllillll
Sbjct

1114

CCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCTG

Query

587

AAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGACCCCTTCCC

Sbjct

1174

AAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGACCCCTTCCC

640

IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIMIIMIIillllllllililll
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Appendix 3. Verification of mcBMP4 insert identify and orientation in pcDNA4/HisMax
mammalian expression vector by DNA sequencing.
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Appendix 4. Verification of mcBMP4 insert identify and orientation in PGEX-KG E. coli
expression vector by BLAST search.
Gallus gallus bone morphogenetic protein 4 (BMP4), mRNA
Score = 647 bits (347), Expect-0.0
Identities = 347/347 (100%), Gaps = 0/347 (0%)
Strand=Plus/Plus

Query

54

CAGCCCCAAGCACCACGGTTCCCGCAAGAACaaaaaactaCTGCCGCCGCCACGCTCTCTA

113

IMIIIMMIIIMIIIMIIIIMIIIIIMIMMIIIIIIIIIIIMMIIIIII!
Sbjct

873

CAGCCCCAAGCACCACGGTTCCCGCAAGAACAAAAAAAACTGCCGCCGCCACGCTCTCTA

932

Query

114

TGTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGC

173

I ] F1111111 i I) I [ 11 [! I i I f I f I! 11 111 I E 1 1 1 1 1 1 1 E 1 1 1 J I F 1 1 1 1 1 1 I 11! 11
Sbjct

933

TGTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGC

992

Query

174

GTTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCA

233

MIIIIIIIIIMIIIIIIMIIIIilllllllllllllMIIIIMIIMMMIIIII
Sbjct

993

GTTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCA

1052

Query

234

CGCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGT

293

IIIIIIIIIIIIIIIIIIIMIilllllllMIIIIIIIIIIIIIIMIIIMIIMIM
Sbjct

1053

CGCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGT

1112

Query

294

GCCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCT

353

IIIIIIIIMMMIIIIIIMMIIIIIIIIIMIIilMIIMIIIIillllllllll
Sbjct

1113

GCCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCT

Query

354

GAAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGAC

Sbjct

1173

GAAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGAC

400

MMIIIMIIIMMIIMIIIMMIIIMIIIIIIIIMIIIII

82

1219

1172

Appendix 5. Verification of mcBMP4 insert identify and orientation in PGEX-KG
E. coli. expression vector by DNA sequencing.
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Appendix 6. Chick BMP4 DNA sequence (Open Reading Frame) and translated chick
BMP4 protein sequence. cBMP4 DNA sequence is showed in black while cBMP4
protein sequence is showed in blue. Mature region of cBMP4 protein is highlighted in
yellow. The potential glycosylation sites are marked in boxed letters.

1

M I P G N R M L M V I L L C Q V L L G G
atgattcctggtaaccgaatgctgatggtcatcctactatgccaagtcctgctgggaggt

60

61

T N H A S L I P E T G R K K V A E L Q G
accaaccatgctagcctgatccccgagaccggcaggaagaaagtcgcagagct[t]caggga

12 0

121
181
241
3 01
3 61
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201

Q A G S G R R S A Q S H E L L R G F E T
caagccggatccggacgccgctctgcccaaagccatgaactcttgcggggtttcgaaacg
T L L Q M F G L R R R P Q P S K S A V I
actctgctgcagatgtttgggctgcga§ggcggccccagcccagcaaatcagccgtcatc
P S Y M L D L Y R L Q S G E E E E R S L
cccagttacatgctggatctctaccggctccagtccggagaagaggaggagaggagcctc
Q E I S L Q Y P E R S A S R A N T V R S
caggagatcagcctgcagtacccggagcgatctgccagccgg|g]ccaacaccgtgaggagc
F H H E E H L E S V P G P S E A P R I R
t|t]ccaccatgaagagcacctggagagcgtgccgggtcccagcgaagcgccgcggatccgc
F V F N L S S V P D N E V I S S E E L R
ttcgtcttcaacctcagcagcgtgccggacaacgaggtgatctcgtcggaggagctgcgg
L Y R E Q V E E P S A A W E R G F H R I
ctgtaccgggagcaggtggaggagccgagcgcggcgtgggagaggggcttccaccggata
N I Y E V M K P L S E R S Q A I T R L L
aacatttacgaagtgatgaagccgctgtcggagcgctcgcaggccattacgcgcctgttg
D T R L V H H N V T R W E T F D V S P A
gacacgcggttggtgcaccacaacgtgacgcgctgggagacctttgatgtgagcccagcc
V I R W T K D K Q P N H G L V I E V T H
gtgatccggtggaccaaggacaagcagcccaaccacgggctggtgatcgaggtgacccac
L H Q A Q T H Q G K H V R I S R S L P Q
ctccaccaggcacagactcatcagggcaaacacgtcaggattagccgatctttacctcag
G H G G D W A Q L R P L L V T F G H D G
gggcacggcggggactgggcgcagctcaggccgctcctggtcaccttcgggcacgacggg
R G H A L T R R A R R S P K H H G S R K
cgaggccacgcgctgacccgcagggcccgccgcagccccaagcaccacggttcccgcaag
N K K N C R R H A L Y V D F S D V G W N
aacaaaaaaaactgccgccgccacgctctctatgtggatttcagcgacgtgggttggaac
D W I V A P P G Y Q A F Y C H G D C P F
gattggatcgtggcccccccgggctaccaggcgttttactgccacggggactgccccttc
P L A D H L N S T N H A I V Q T L V N S
cctctggccgaccacctcaactccaccaaccacgccatcgtgcagacgttggtcaactcc
V N S S I P K A C C V P T E L S A I S M
gtcaactccagcatccccaaggcctgctgcgtgcccacggagctgagcgccatctccatg
L Y L ' D E Y D K V V L K N Y Q E M V V E
ctctacctggatgagtatgacaaggtggtgctgaaaaactaccaggagatggtggtggag
G C G C R *
gggtgcgggtgccgctga

84

180
240
3 00
3 GO
420
4 80
540
600
660
720
780
84 0
900
960
1020
10 80
114 0
1200

Appendix 7. List of commonly used abbreviations in this study.

Abbreviation

Full Term

AVCD

atrioventricular canal defect

ASP

atrial septum primum

OT

outflow tract

AVC

atrioventricular canal

EMT

epithelial-mesenchymal transformation

TGF-/3

transforming growth factor- (8

BMP

bone morphogenetic proteins

PBSM

parabronchial smooth muscle

IPTG

isopropyl-/3-D -thiogalactoside

YTA

Trytone yeast ampicillin

GST

1 -chloro-2,4-dinitrobenzene

CDNB

1 -chloro-2,4-dinitrobenzene

GST

glutathione S-transferase

KLH

keyhole limpet hemocyanin

GLUT

glutaraldehyde

PMSF

phenylmethanesulphonylfluoride or
phenylmethylsulphonyl fluoride)
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